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1 Introduction 
1.1 The liver - an important gland of the gastrointestinal tract 
1.1.1 The liver’s most important task is its major risk: detoxification 
Beside the pancreas, the liver is the most important gland of the 
gastrointestinal tract and with a weight of 1.4 to 1.8 kg the biggest gland of the 
human body. As a central metabolic organ, it is supplied with aliment of the 
digestive system, which is processed into several nutrients like glycogen, 
plasma proteins and fatty acids. In addition to its functions in metabolism, 
biosynthesis, excretion and secretion the liver is essentially involved in 
detoxification of absorbed substances (Malhi et al. 2006). Accordingly, the liver 
is continuously exposed to toxic noxae resulting in a high risk of hepatocytes for 
undergoing cell death (MLP Duale Reihe, Anatomie, 2007). As a marker for liver 
damage, activation of Alanine-Aminotransferase (ALT) and Aspartat-
Aminotransferase (AST) can be determined. While ALT is a very specific liver 
enzyme, AST levels can also be additionally elevated in heart, kidney and 
skeletal muscle tissue. However, increased AST values also serve as an 
indicator for severe injury due to its main location in mitochondria (Malhi et al. 
2010). 
1.1.2 Induction of liver injury triggers compensatory hepatic 
regeneration 
Different cell types are located in the liver. Hepatocytes are the parenchymal 
cells of the liver and constitute the largest hepatic cell population. Hepatocytes 
are polyhedral cells with a diameter of 20 – 30 µm consisting of two to four 
nuclei. Hepatocytes have two poles: the apical one, which forms the gale 
capillary side, and the basolaterale surface, which turns either to different 
hepatocytes or to the “space of Disse” which is a with blood-plasma filled space 
between the discontinuous endothelium and the hepatocytes (Lüllmann Rauch 
2003). Under healthy conditions, only 0.001 – 0.01 % of hepatocytes proliferate 
at any given time (Diehl & Rai 1996, Michalopoulos & DeFrances 1997). In 
cases of liver injury such as surgical partial hepatectomy (PH) or toxic cell 
death, hepatocytes transiently leave their state of quiescence and start to 
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proliferate until the original liver mass is restored. This unique compensatory 
capacity of the liver is actually not a true regeneration as the liver morphology is 
not fully restored, but rather reflects a compensatory hyperplasia (Koniaris et al. 
2003). In addition, after acute liver injury, as triggered for example by toxic 
substances, hepatic stem cells are sometimes involved in tissue repair 
(Michalopoulos 2007). These stem cells are termed Oval cells and are located 
in a single layered epithelium surrounding the Canals of Hering which is a 
continuation of gale fluid leading Canaliculi biliferi. Moreover, two other 
important cell types are located in the liver: Kupffer-cells are defined as the 
resident macrophages in the liver. They belong to the mononucleous 
phagocytes system (MPS) which is associated to the sinusendothelian cells and 
have the ability to phagocytize bacteria, cell debris or aged erythrocytes. Ito-
cells are fat-saving hepatic stellate cells situated in the Space of Disse. These 
cells can be activated upon liver injury and transactivate into collagen-producing 
myofibroblasts, which is the basis for formation of liver fibrosis and cirrhosis 
(MLP Duale Reihe, Anatomie 2007). 
1.2 Apoptosis and necrosis in the liver – different triggers, but 
similar outcomes 
Two mechanisms, apoptosis and necrosis, are frequently involved in acute and 
chronic liver injury. While necrosis has classically been viewed as an accidental 
and un-regulated form of cell death, apoptosis is a precisely regulated and 
genetically determined process that can be induced via death receptor-
mediated, extrinsic pathways or through intrinsic mechanisms activated by 
intracellular stress. Due to its strict genetic regulation, apoptosis has been 
assigned a function for the directed elimination of dysfunctional or even 
dangerous cells (Liedtke 2011). 
1.2.1 Extrinsic and intrinsic apoptosis signaling pathways  
Apoptosis is a process of tightly coordinated cell death which is 
morphologically characterized by cell membrane blebbing, shrinkage, chromatin 
condensation and nuclear fragmentation. As a result of apoptosis apoptotic 
bodies are formed. These cellular leftovers are subsequently phagozytised by 
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Kupffer cells (Canbay et al. 2003a, Canbay et al. 2003b, Johansson et al. 
2003).  
 
 
 
 
 
 
 
 
 
Figure 1.1: Extrinsic pathway of apoptosis. In extrinsic apoptosis, the signal is 
mediated through external death ligands and ligand-receptor interaction resulting in activation of 
Casp8 and subsequent proteolytic activation of effector caspases such as Caspase 3 (Casp3). 
In turn, Casp3 degrades several proteins that are important for cell survival. As an example, the 
Inhibitor of caspase-activated DNase (ICAD) is shown which is converted to caspase-activated 
DNase (CAD) by Casp3 allowing efficient DNA degradation.  
In contrast to necrosis, apoptosis is triggered by specific stimuli such as 
the TNF superfamily of death ligands (e.g. TNF, Fas, TRAIL). Two apoptotic 
signaling pathways have been defined depending on the inducing stimuli: in the 
extrinsic signaling pathway, apoptosis is induced by external signals such as 
the death ligands Fas, TRAIL or TNF (Malhi et al. 2006). Binding of these 
ligands to their cognate death receptors leads to the induction of cysteine-
dependent aspartate specific proteases (caspases) (Omata et al. 2007). The 
apical caspase to be activated is the initiator caspase, Caspase-8 (Casp8). 
However, besides its relevance for inducing apoptosis, Casp8 may also 
regulate several other cellular functions such as proliferation, differentiation and 
NF-κB-activation (Maelfait & Beyaert 2008). Recent data also suggested a 
novel function of Casp8 for the prevention of an alternative mode of cell death 
termed necroptosis (Liedtke et al. 2011, Oberst & Green 2011) which could 
FADD
Casp8 Casp3
ICAD CAD
Death ligand
Death receptor
Pro-apoptotic
Anti-apoptotic
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contribute to tumor suppressive properties. Nevertheless, the main function of 
initiator caspases such as Casp8 is the activation of downstream executer 
caspases such as Caspase 3, 6 and 7. These executer caspases eventually 
induce the actual process of cell death by proteolytic degradation of proteins 
involved in maintenance of cell architecture, homeostasis, survival and DNA 
stability (e.g. ICAD) (Taylor et al. 2008).  
Alternatively, apoptosis can be induced through intrinsic mechanisms. 
Intracellular stress (e.g. DNA-damage) may induce pro-apoptotic members of 
the Bcl-2 protein family (e. g. Bax and Noxa) resulting in mitochondrial outer 
membrane permeabilization (MOMP). Several activators of intrinsic apoptosis 
such as cytochrome c, second activator of mitochondrial apoptosis (SMAC), 
endonuclease G, high temperature requirement A2 (HrtA2) and apoptosis-
inducing factor (AIF) are released into the cytosol (Rasola & Bernardi 2007). 
Cytochrome c release into the cytosol promotes formation of a protein complex 
termed apoptosome consisting of Caspase 9 and apoptosis activating factor-1 
(APAF-1) (Danial & Korsmeyer 2004, Green & Kroemer 2004). This complex 
eventually activates Caspase 9 and subsequently results in the activation of 
executer caspases and cell death. 
It has been proposed that the main function of apoptosis might be the 
elimination of injured cells. For instance, gamma irradiation can lead to DNA 
damage, genetic instability and thus to malignant transformation of cells. 
Several mechanism exist to repair DNA damage (e.g. activation of tumor 
suppressor protein p53 (Selivanova & Wiman 1995) or p27 (Qin & Tang 2002)). 
However, if the DNA repair machinery fails, the injured cells can alternatively be 
driven into p53-dependent, intrinsic apoptosis (Cheah & Looi 2001, Wang et al. 
2003). Therefore, p53 has been termed “guardian of the genome” (Lane 1992). 
Accordingly, p53 mutations are frequently associated with cancer and are 
considered a predisposition factor of hepatocarcinogenesis (Hagiwara et al. 
2006). 
1.2.2 Mechanisms and morphology of necrotic cell death 
In contrast to apoptosis, functions and pathways related to necrosis are 
less understood. Necrosis is the result of oncosis, which is characterized by 
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cellular swelling and cell blebbing eventually leading to membrane breakdown 
(Lemasters et al. 1981). Necrosis is a consequence of metabolic injury, such as 
acute drug-induced hepatotoxicity or ischemia, resulting in ATP depletion (Malhi 
et al. 2006). This leads to a metastable state including mitochondrial 
depolarization, lysosomal breakdown and failure of ionic pumps (Gores et al. 
1989) which results in cell dissolving and finally in cell death. In contrast to 
apoptosis, the dead cells and debris resulting from necrosis are not 
phagozytised by macrophages, but rather induce an inflammatory response 
e.g., by stimulating Toll-like receptors (TLR) (Naugler & Karin 2008). It has been 
suggested that necrosis-induced inflammation could mechanistically link 
necrosis with tumor growth (Vakkila & Lotze 2004) by inducing pro-inflammatory 
cytokines such as interleukin-6 (IL-6) or TNF, which also play a crucial role in 
tumorigenesis (Naugler & Karin 2008). Interestingly, several triggers such as 
oxidative stress can induce both modes of cell death, e.g., apoptosis and 
necrosis, respectively (Malhi & Gores 2008). However, the molecular switch 
between these two cell death pathways is largely unknown so far. 
1.3 The experimental animal model of Diethylnitrosamine-
induced tumorigenesis 
Diethylnitrosamine (DEN) belongs to the substance group of the 
nitrosamines and has been characterized as a carcinogenic reagent. DEN is 
metabolized predominantly in the liver into an alkylating agent inducing DNA 
mutations (Verna et al. 1996) and hepatocyte death (Farber & Gerson 1984). 
Briefly, DEN is hydroxylated by cytochrome P450, an enzyme with the highest 
activity in the centrilobular hepatocytes, into α-hydroxylnitrosamine (Verna et al. 
1996). The acetaldehyde residue is cleaved and an electrophilic ethyldiazonium 
ion is formed. This ion is the trigger for DNA damage by reacting with DNA-
bases (Heindryckx et al. 2009). Treatment of mice with DEN for several weeks 
rapidly induces tumorigenesis (Bralet et al. 2002), and causes formation of 
hepatocellular carcinoma (HCC) with high incidence in male mice (90 - 100 %) 
and to a much lesser extend (10 – 30 %) in female mice (Naugler et al. 2007). 
Several studies indicated that DEN induces liver cancer in a dose-dependent 
manner (Williams et al. 2000). Initially, DEN has been described as an agent 
solely inducing HCC. However, more recent studies indicate that DEN may also 
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induce pro-inflammatory pathways in the liver. In this context, Kupffer cells are 
activated on the basis of the DEN-induced hepatocellular damage. These cells 
produce hepatomitogens such as IL-6 promoting compensatory proliferation of 
surviving hepatocytes (Naugler et al. 2007, Maeda et al. 2005). Moreover, 
recent studies showed that DEN also triggers chromosomal instability – and 
down-regulation of tumor suppressor genes such as Runx3 and NrOb2/Shp, 
which potentially further triggers tumor initiation (Aleksic et al. 2011).  
1.4 Mechanisms of Hepatocarcinogenesis  
Hepatocarcinogenesis proceeds through a multi-step process that can 
best be monitored by histological analysis.  Basically, two models have been 
postulated to explain the origin of hepatic cancer cells: Multiple evidences 
suggested that genetic or epigenetic modification of mature hepatocytes may 
lead to malignant transformation and subsequent development of liver cancer. 
Alternatively, some evidence exists that HCC may also originate from cancer 
stem cells (Mishra et al. 2009). These two hypotheses are supported by two 
common theories: Knudson’s two hit hypothesis and the cancer stem cell 
theory. In 1953, Knudson’s hypothesis postulated that a first pro-tumorigenic hit 
(e.g. a mutation) can result in formation of dysplastic nodules. These are 
characterized by abnormal cytological features including clear cell changes and 
nuclear crowding. A second hit may then lead to marked genomic instability with 
loss of the tumor suppressor gene p53 defining the time point of malignant 
transformation into a HCC cell. During hepatocarcinogenesis, dysplastic tissue 
first forms well differentiated tumors, which can be modulated into a moderately 
differentiated or a poorly differentiated HCC. The latter one represents the most 
malignant form of primary liver cancer. With the loss of differentiation, the 
potential of invading the surrounding fibrous stroma and vessels as well as the 
capacity to form metastasis increase (Farazi & DePinho 2006).  
A proto-typical example for the development of HCC is the chronic viral 
hepatitis induced by HBV- or HCV-infection. Viral hepatitis typically results in 
chronic hepatic cell death (apoptosis or necrosis) and subsequent continuous 
cycles of compensatory proliferation. As a negative side effect of chronic liver 
injury and compensatory proliferation, the hepatic tissue repair ultimatively 
results in formation of liver fibrosis and cirrhosis. At this stage, hyperplastic 
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nodules can consist of focal regenerating hepatocytes with normal cytological 
features, but are meant as a potential first step towards HCC. Continuous liver 
regeneration can result in genetic or epigenetic alterations such as activation of 
oncogenes or inactivation of tumor suppressors which represents Knudson’s 
second hit (Spangenberg et al. 2009). 
 
A       B 
 
 
 
 
 
 
 
Figure 1.2: A. Normal stem cell pathway. B. Cancer stem cell theory. In healthy conditions, 
pluripotent cells (blue) divide into two daughter cells. One stays pluripotent, whereas the other 
one differentiate into a specific cell (green). The cancer stem cell theory postulates a de-
regulation of pluripotent cells: Differentiation fails and aberrant stem cells (red) do not stop to 
proliferate.  
 
In contrast to the 2-hit hypothesis, the cancer stem cell theory postulates 
that tumors originate from the transformation of progenitor cells or tissue stem 
cells (Gupta et al. 2009). Stem cells show two special features: they have the 
ability for self-renewal and the capacity to differentiate into specific cells of the 
tissue of origin (Trosko & Chang 1989). Stem cells are immortal until they 
differentiate.  Under normal conditions, an activated stem cell divides into two 
daughter cells with one differentiating into a specialized cell, while the other one 
remains pluripotent (Figure 1.2 A).  
Proliferation of the stem cell pool without differentiation may increase the 
potential of malignant degeneration (Figure 1.2 B). It has been postulated that 
tumor initiation prevents the differentiation of stem cells and could therefore be 
the first step in tumorigenesis (Potter 1978, Trosko & Chang 1980).  
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Several modes of acute liver injury, such as aflatoxin intoxication or 
DEN-treatment may not only lead to hepatocytes proliferation, but also to 
activation of liver stem cells (Michalopoulos 2007).  Interestingly, 28 - 50 % of 
patients with HCC contain cells expressing markers of hepatic progenitor cells 
(oval cells) such as CD133+ or cytokeratin 19 (CK19) (Roskams 1998, 
Roskams et al. 2006, Zhou et al. 2007). CD133+, also known as Prominin 1, is 
a five-transmembrane cell surface glycoprotein (Miraglia et al. 1997, Yin et al. 
1997, Shmelkov et al. 2005). CD133+ positive stem cells seem to be involved in 
tumorigenesis in brain, prostate, and colon cancer (Singh et al. 2003, Singh et 
al. 2004, Hemmati  et al. 2003, Richardson et al. 2004, O’brien et al. 2007,  
Ricci-Vitiani et al. 2007). Recently, it has been suggested that CD133+ positive 
stem cells isolated from bone marrow are able to repopulate up to 10 % of the 
normal liver when transplanted (Gehling et al. 2005,  am Esch et al. 2005). 
Moreover, several studies suggested that CD133+ positive cells isolated from 
HCC tissue showed significant tumorigenic capacity (Ma et al. 2007, Yin et al. 
2007). Using human HCC cell lines, it was demonstrated that CD133+ 
expression defines an aggressive cancer stem cell phenotype. In the adult 
murine liver, CD133+ expression identifies a population of oval cells with the 
gene expression profile and function of primitive, bipotent liver stem cells (Ma et 
al. 2007, Yin et al. 2007,  Fujii et al. 2010, Tsuchiya et al. 2009).  
1.4.1 DMBT1 – a multi-functional protein with a putative role for oval 
cell differentiation in the liver 
Very recent data indicated a mechanistical link between a population of 
liver stem cells (Oval cells), hepatitis B virus-related liver diseases and de-
regulation of a poorly investigated protein called Deleted in Malignant Brain 
Tumors 1 (DMBT1) (Deng et al. 2012). DMBT1 is de-regulated in several 
cancers (Mori et al. 1999, Takeshita et al. 1999, Wu et al. 1999, Mollenhauer et 
al. 2004) including medullablastoma (Mollenhauer et al. 1997). In addition, two 
further functions of DMBT1 have been discussed: First, DMBT1 affects innate 
immunity and mucosal protection (Tynan et al. 2005) by interacting with 
pathogens (e.g. streptococci, helicobacter, influenza viruses) and mucosal 
defense proteins (e.g. IgA and surfactant proteins) (Ligtenberg et al. 2007). 
More importantly, DMBT1 seems to be involved in epithelial and stem cell 
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differentiation (Tynan et al. 2005). In line with these conclusions, DMBT1 seems 
to have a direct effect on differentiation of oval cells into hepatocytes (Deng et 
al. 2012). 
1.4.2 Tumor development involves de-regulation of cell cycle 
regulators 
The current accepted hypothesis postulates that tumors arise through a 
multistep process involving (i) generation of somatic mutations and (ii) de-
regulation of tumor suppressor genes and oncogenes (Fearon & Dang 1999). 
Many tumor suppressor genes encode proteins known to limit cell cycle activity. 
For instance, proteins of the INK4 (Inhibitor of Cdk4) family and the cip/kip 
family (CDK interacting protein/Kinase inhibitory protein) including p57, p21 and 
p27 inhibit cyclin-dependent kinases (CDKs) which are essential for cell 
proliferation (Malumbres & Barbacid 2005). Accordingly, due to their inhibiting 
function, CDK-inhibitors (CDIs) may act as tumor suppressors and a loss-of-
function mutation of CDIs could lead to an up-regulation of CDKs, which may 
endanger for a higher risk of tumorigenesis. Besides its function in halting 
cellular proliferation, p21 also promotes differentiation and cellular senescence 
(Abbas & Dutta 2009). Moreover, it mediates p53-dependent G1 growth arrest 
(Deng et al. 1995, Brugarolas et al. 1995) and interacts with Proliferation Cell 
Nuclear Antigen (PCNA) which plays an important role in S phase DNA 
replication and DNA damage repair. Of notice, increased p21 expression 
correlates significantly with incidence in patients with HCV-associated chronic 
liver disease. Moreover, cytoplasmic p21 is associated with HCCs, especially in 
moderately and poorly differentiated tumors (Abbas & Dutta 2009).  
In comparison, a second cell cycle inhibitor, termed p27, is highly 
expressed in early stages of HCC (Yachida et al. 2008), presumably as a 
protective cell mechanism. However, p27 is usually down-regulated in HCC with 
severe tumor grade or recurrence of tumors (Tannapfel et al. 2000, Fiorentino 
et al. 2000, Armengol et al. 2003). Of interest, p27 is inhibited by RIP1 (the 
death domain-containing kinase receptor-interacting protein 1) (Liang & 
Slingerland 2003) which in turn can be proteolytically degraded by Casp8 
(Vandenabeele et al. 2006). Recent data indicate that absence of Casp8 leads 
to an accumulation of RIP1 and may result in necrosis-like cell death 
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(necroptosis, Liedtke et al. 2011). Moreover, recent data suggested non-
apoptotic functions of Casp8 eventually affecting cell cycle regulation, although 
the precise mechanisms are poorly understood (Maelfait & Beyaert 2008).  
Proto-oncogenes are cell cycle promoting proteins, e.g. mitogens or 
transcription factors, which are also expressed in healthy cells. However, if 
proto-oncogenes are de-regulated, they may convert into active oncogenes and 
trigger increased proliferation and tumorigenesis. In this context it is 
controversially discussed if the pro-survival transcription factor NF-κB might be 
a proto-oncogene. In its inactive form, the NF-κB subunits (e.g. p50, p65) are 
sequestered into the cytoplasm. Activation of the IκB kinase complex (IKK), 
consisting of the three subunits IKKα, IKKβ and IKKγ/NEMO, eventually leads to 
nuclear translocation of p50 and p65 and subsequent activation of target gene 
transcription (Leeman & Gilmore 2008). NF-κB is involved in many processes 
such as cell survival, inflammation (Sarkar et al. 2008), cancer cell invasion and 
angiogenesis (Helbig et al. 2003, Huang et al. 2001, Samant et al. 2007). 
Increased levels of NF-κB are detected especially in poorly differentiated 
cancers (Karin 2006). However, mice lacking NEMO in hepatocytes are unable 
to activate NF-κB in the liver and develop spontaneous liver apoptosis and 
hepatocellular carcinoma (Luedde et al. 2005). Thus, it is still under debate if 
NF-κB is rather a proto-oncogene or a tumor suppressor (Liedtke & Trautwein 
2012).  
Aim of the present study 
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2 Aim of the present study 
 Caspase-8 (Casp8) is the most apical caspase in the extrinsic apoptosis 
pathway. In the past years the functions of Casp8 for suppression of 
hepatocarcinogenesis have been controversially discussed. On the one hand, 
Casp8 is frequently down-regulated or absent in murine HCCs (Liedtke et al. 
2005) hinting at a tumor suppressive property of this protease. On the other 
hand, Casp8 was shown to be essential for spontaneous hepatocarcinogenesis 
in mice lacking the NF-κB essential modulator (NEMO) suggesting that Casp8 
could act as a tumor promoter in the liver in an inflammatory environment  
(Liedtke et al. 2011). The aim of the present study was the investigation of 
tumor suppressive and oncogenic properties of Casp8 in the diethylnitrosamine 
(DEN) model of chemically-induced acute liver injury and hepatocarcinogenesis, 
respectively. It was hypothesized that loss of Casp8 would enhance either 
tumor initiation or tumor progression in the liver.   
To test this hypothesis, two experimental models should be applied to 
mice lacking Casp8 specifically in hepatocytes: In the first model, DEN should 
be applied at low dose to induce HCC. The specific aim of this experiment was 
to evaluate if Casp8-deficient mice would reveal aberrant tumor incidence or 
tumor progression. Moreover, the expression levels of prominent oncogenes 
and tumor suppressors were supposed to be analyzed in Casp8-deficient tumor 
tissues. In the second model, DEN should be applied at high dose to induce 
acute liver injury and compensatory liver regeneration with the aim to 
determine, if Casp8 would be involved in the immediate response towards 
genotoxic liver injury and its postulated function for elimination of premalignant 
hepatocytes.  
 It was anticipated that these investigations may help to evaluate a 
therapeutically benefit of caspase inhibitors in patients suffering from hepatitis. 
Recent studies showed that caspase-inhibitors reduced hepatocytes apoptosis, 
liver injury, hepatic inflammation and hepatic fibrosis (Canbay et al. 2003). The 
present study may clarify if these benefits in treatment of liver disease are 
accompanied by an increased risk of hepatocarcinogenesis. 
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3 Material and Methods 
3.1 Material 
3.1.1 Chemicals 
Reagent Manufacturer 
Acetic acid (glacial) 100 % (CH3COOH) Merck, Darmstadt 
Acetone (C3H6O) VWR, Darmstadt 
Agarose (Electrophoresis Grade) Serva, Heidelberg 
Ammoniumpersulfate (APS) Roth, Karlsruhe 
Bromophenol Blue Bio-Rad, Munich 
BSA (Bovine Serum Albumin)  Sigma, Steinheim 
Calciumchloride (CaCl2) Sigma, Steinheim 
CHAPS (C32H58N2O7S) Sigma, Steinheim 
Chloroform (CHCl3) AppliChem, Darmstadt 
Diethylether  Baker Chemicals, 
Griesheim 
DTT (Dithiothreitol) (C4H10O2S2) Sigma, Steinheim 
EDTA (Ethylene Diamine Tetraacetate) AppliChem, Darmstadt 
EGTA (Ethylene glycol tetraacetic acid)  AppliChem, Darmstadt 
Eosin Sigma, Steinheim 
Ethanol (C2H5OH)  AppliChem, Darmstadt 
Ethidium bromide (C21H20BrN3) Invitrogen, Karlsruhe 
Formamide AppliChem, Darmstadt 
Formaldehyde 37 % (CH2O) Roth, Karlsruhe 
Glucose (C6H12O6) Merck, Darmstadt 
Glutaraldehyde (C5H8O2) Roth, Karlsruhe 
Glycerol gelatin  Sigma, Steinheim 
Glycine (C3H5(OH)3) AppliChem, Darmstadt 
Goat Serum Promocell, Heidelberg 
Hematoxylin Sigma, Steinheim 
HEPES (C6H18N2O4S)  Roth, Karlsruhe 
Hydrochloric acid (HCl) Merck, Darmstadt 
Isopropyl alcohol (C3H8O) AppliChem, Darmstadt 
Magnesium chloride (MgCl2)  Merck, Darmstadt 
β-Mercaptoethanol  AppliChem, Darmstadt 
Methanol (CH4O) VWR, Darmstadt 
MOPS (3-[N-Morpholino] propanesulfonic acid)  Sigma, Steinheim 
Nonidet P – 40  AppliChem, Darmstadt 
Paraformaldehyde (CH2O)n) Roth, Karlsruhe 
Phenylmethylsulfonyl fluoride (PMSF) Roth, Karlsruhe 
Ponceau S  Sigma, Steinheim 
Potassium chloride (KCl) Merck, Darmstadt 
Salicylic acid  Sigma, Steinheim 
Sodium carbonate (Na2CO3) Merck, Darmstadt 
Sodium hydrogencarbonate (NaHCO3) Merck, Darmstadt 
SDS (Sodium Dodecylsulfate) NaC12H25SO4) Roth, Karlsruhe 
Sodium fluoride (NaF)  Sigma, Steinheim 
Sodium vanadate (Na3VO4)  Sigma, Steinheim 
Sulfosalicylic acid Merck, Darmstadt 
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Trichloracetic acid (C2HCl3O2) Merck, Darmstadt 
Tri-sodium citrate dihydrate (Na3C6H5O72HCl) Roth, Karlsruhe 
TEMED (Tetramethylethylendiamine)  Bio-Rad, Munich 
Tris (C4H11NO3) AppliChem, Darmstadt 
Triton X-100 Roth, Karlsruhe 
Trypan blue stain 0.4% Gibco 
TWEEN-20 Sigma, Steinheim 
Xylene VWR, Darmstadt 
3.1.1.1 Radiochemicals 
Product Manufacturer 
[32P]-γ-ATP (10mCi/ml)  Hartmann Analytic 
3.1.2 Instruments and Equipment 
Product Manufacturer 
Wallac β-scintillation counter Perkin Elmer, Jügesheim 
Botting Trans-BlotTM Cell  BioRad, Munich 
Bright Field Microscope DM1000 Leica, Wetzlar 
Centrifuge Tabletop 5417 Eppendorf, Hamburg 
Cryostat HM 550  MicromThermo Scientific, 
Dreieich 
Cold light source KL 1500 LCD Schott AG, Mainz 
DISKUS Z16 APO Leica, Wetzlar 
ELISA Reader µQuant +KC4 Software BIO-TEK, Bad 
Friedrichshall 
FUJI FILM LAS-4000 FUJI FILM Europe, 
Düsseldorf 
Gel chamber Subcell GT Biorad, Munich 
Gel chamber  Peqlab, Erlangen 
Microcentrifuge IR 220 VAC  Roth, Karlsruhe 
pH Meter PB-11  Sartorius, Goettingen 
7300 Real Time PCR System  
+ Sequence Detection Software Version 1.3.1. 
Applied Biosystems, 
Darmstadt 
Shaking incubator Unimax 1010  Heidolph, Nürnberg 
Thermocycler T3000 and Tpersonal  Biometra, Göttingen 
Thermomixer 5436  Eppendorf, Hamburg 
Vortex Reax top  Heidolph, Nürnberg 
3.1.3 General material 
Product Manufacturer 
Cryotubes (1,5 ml) BD, Erlangen 
Hybond N membranes  Amersham Pharmacia 
Biotec Europe, Nümbrecht 
Nitrocellulose membrane Protran®  Whatman, Dassel 
X ray films  Amersham Pharmacia 
Biotec Europe, Nümbrecht 
3.1.4 Material for animal experiments 
Product Manufacturer 
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General chow for rodents Altromin, Lage 
Hematocrit capillary  Hirschmann Laborgeräte, 
Eberstadt 
Injection needles Sterican® Braun, Melsungen 
Micro tube (1,1 ml Z-Gel) Sarstedt, Nümbrecht 
Sodium chloride 0.9 % (NaCl) Delta Select, Dreieich 
Sterile gossamer (Sterilkompresse®) Beese, Barsbüttel 
Surgical instruments FST, Heidelberg 
Syringe Omnican® Braun, Melsungen 
 
3.1.5 Antibodies 
3.1.5.1 Primary antibodies 
Product Manufacturer 
c-Jun (N) Santa Cruz Biotechnology, Inc. 
CD 11b BD Pharmingen 
CD 45 ebiosciences 
CK 19 Santa Cruz Biotechnology, Inc. 
DMBT1 Gift from J. Mollenhauer, 
Copenhagen 
F4/80 AbD Serotec 
GAPDH AbD Serotec 
Ki67 Dianova GmbH 
JNK1 (FL) Santa Cruz Biotechnology, Inc. 
p21 Santa Cruz Biotechnology, Inc.  
NF-κB p65 Santa Cruz Biotechnology, Inc. 
Phospho-c-Jun (Ser73)  Cell Signaling Technology 
Phospho-Histone H3 (Ser10) Cell Signaling Technology 
NF-κB p65 (A) Santa Cruz Biotechnology, Inc. 
NF-κB p50 (NLS) x for EMSA Santa Cruz Biotechnology, Inc. 
NF-κB p65 (A) x for EMSA Santa Cruz Biotechnology, Inc. 
3.1.5.2 Secondary HRP-labeled antibodies  
Product Manufacturer 
anti-mouse IgG, HRP-linked Cell Signaling Technology 
3.1.5.3 Secondary fluorochrome-conjugated antibodies for fluorescence 
microscopy 
Product Manufacturer 
Alexa 488 donkey anti-mouse Invitrogen 
Alexa 488 rabbit anti-rat Invitrogen 
Alexa 546 goat anti-rabbit Invitrogen 
Alexa 546 rabbit anti-goat Invitrogen 
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3.1.6 Standard buffers 
Product Manufacturer 
Phosphate buffered saline (PBS) PAA, Cölbe 
Restore Western Blot Stripping Buffer Thermo Scientific, Bonn 
Roti Block 10x Roth, Karlsruhe 
Rotiphorese 10x SDS PAGE Roth, Karlsruhe 
TAE 50x AppliChem, Darmstadt 
3.1.7 Analytical chemicals, reagents, enzymes and kits 
Product Manufacturer 
Acrylamide Solution 30 % Biorad, Munich 
BIO-RAD Protein Assay Bio-Rad, Munich 
Block and Sample Promega, Mannheim 
Complete Mini® (protease inhibitors) Roche, Mannheim 
Covering solution for cryosections (Tissue-Tek®) Dako, Hamburg 
Diaminobenzidine tablets (DAB) Sigma, Steinheim 
Dako Pen Dako, Hamburg 
DNA marker 1kb plus Ladder® Invitrogen, Karlsruhe 
ECL-Western-Blot-analysis Solution® Pierce, Bonn 
HotStarTaqTM Master Mix Qiagen, Hilden 
Omniscript RT Kit Qiagen, Hilden 
Oligo dT primer Qiagen, Hilden 
Pefabloc SC Protease Inhibitor Roth, Karlsruhe 
Peq Gold RNA PureTM PeqLab, Erlangen 
Peroxidase Blocking Solution Dako, Hamburg 
Primer MWG Biotech AG, 
Ebersberg 
Proteinase K Solution AppliChem, Darmstadt 
Protran Membrane Whatman, Dassel 
ReadyMixTM redtaqTM PCR reaction mix with 
MgCl2 
Sigma, Steinheim 
Red Taq Sigma, Steinheim 
Restore Western Blot Stripping Buffer Thermo Scienticific 
RNAse Sigma, Steinheim 
Rotiblock Roth, Karlsruhe 
Roti Histokit Roth, Karlsruhe 
Rotiphorese 10x SDS Page Roth, Karlsruhe 
SYBR® GreenERTM qPCR SuperMix Invitrogen, Karlsruhe 
TAE Puffer 50x AppliChem, Darmstadt 
Trypsin Inhibitor Sigma, Steinheim 
TUNEL Kit Roche, Mannheim 
Ultraspec II RNA Biotecx Laboratories, 
Houston, USA 
Vectashield Mounting Medium with Dapi Dako, Hamburg 
Vectastain ABC Kit Dako, Hamburg 
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3.2 Methods 
3.2.1 Animal maintenance and treatments 
All mouse strains were initially bred and maintained in a specific 
pathogen-free facility of the University Hospital Aachen in a temperature-
controlled room with 12 hours light/dark cycles and free access to standard food 
and water. All experiments were performed in accordance with the German 
legislation on protection of animals and approved by the government of the 
state North Rhine-Westphalia (LANUV, AZ 8.87-50.10.35.08.284). The 
generation and breeding of hepatocyte-specific Caspase-8 knockout mice 
(Casp8∆hepa) and the use of appropriate control mice (Casp8f/f) has been 
described recently (Liedtke et al. 2011). For genotyping of genetically modified 
mice, tail biopsies were taken after weaning and ear marking and subjected to 
genomic DNA extraction and subsequent PCR analysis according to standard 
procedures (for primer sequences see 3.2.5). 
To induce hepatocellular carcinoma (HCC), a single dose of DEN (25 
mg/ kg body weight) was injected intraperitoneally (i.p.) into male mice at two 
weeks of age. After 24 or 40 weeks on normal chow, mice were sacrificed and 
livers were analyzed for macroscopic, histologic and molecular signs of tumor 
formation. Immediately after sacrifice, visible liver tumors were counted and the 
size was measured and documented using a Z16 APO macroscope (Leica) with 
DISCUS software (Hilgers, Königswinter, Germany). 
To induce acute liver damage, 6 - 8 week old male animals were injected 
with DEN at a dose of 200 mg/ kg body weight i.p. Livers were removed 24 - 96 
hours after treatment and subjected to molecular and histological analysis. 
3.2.2 Blood sampling and serology 
Retro-orbital sampling was performed in mice under transient anesthesia 
using isoflurane by penetrating the retro-orbital sinus with a glass capillary. 
Blood samples were collected in a serum tube and centrifuged at 12000 rpm for 
10 minutes. Serum was transferred into a fresh tube and stored at -20 °C. 
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Serumtransaminases (Alanine-Aminotransferase (ALT); Aspartate-
Aminotransferase (AST)) are specific markers for liver damage. In this study, 
aminotransferases were analyzed from murine blood. Subsequently, 
measurements were performed in the clinical routine laboratories of the Institute 
of Clinical Chemistry and Pathobiochemistry, UK Aachen. 
3.2.3 Extraction and sectioning of complete livers 
Mice were sacrificed by cervical dislocation to remove the full liver. The 
abdominal cavity was cut open along the Linea alba. Two relaxation cuts were 
placed along the costal arch at the lateral abdominal walls and the liver was 
removed by dissecting the ligaments. Subsequently, after removing the gall 
bladder, equal parts of liver tissue were either fixed in 4 % formaldehyde/PBS 
for paraffin embedding, snap frozen in liquid nitrogen and stored at -80 °C or 
embedded in Tissue-Tek and stored at -80 °C.  
 Using the liver paraffin blocks serial whole organ 4 µm sections were 
performed and subsequently stained with Hematoxylin and Eosin (HE) or 
subjected to immununhistological stainings following routine protocols.  
3.2.4 RNA extraction, cDNA preparation, Real-Time PCR 
RNA was extracted from mouse livers using peqGOLD RNA PureTM 
(Peqlab) following manufacturer’s instructions. Briefly, a piece of liver tissue 
was minced in peqGOLD RNA with an electric homogenizer. Lysates were 
incubated at room temperature for five minutes. After addition of 0.2 volumes of 
chloroform to the supernatants followed by centrifugation at 12000 g, the upper 
phases were incubated 10 minutes with isopropanol and RNA was pelleted by 
centrifugation at 12000 g and 4 °C. The pellets were washed two times with 1 
ml of 70 % ethanol, air dried for five minutes and eluted in RNAse-free water. 
RNA was quantified by spectrophotometry at an optical density (OD) of 260 nm 
using dH2O as blank. 1 OD260 corresponds to 40 µg RNA/ ml.   
For gene expression analysis, single stranded mRNA was converted into 
complementary DNA (cDNA) by reverse transcription (RT). RT was performed 
using an Omniscript kit (Quagen) according to the manufacturer’s protocol. The 
reaction was composed as subsequently listed in a total volume of 20 µl and 
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incubated in a PCR thermocycler at 37 °C for 60 minutes followed by a 
termination at 95 °C for five minutes. Subsequently, the reaction was cooled to 
4 °C. After RT, samples were diluted 1:200 with purified water and used for 
quantitative real-time PCR or alternatively stored at -20 °C.  
Reverse transcription reaction mix Volume / Reaction 
10x Buffer RT 2 µl 
dNTP mix 2 µl 
Oligo-dT primer 10 µM 2 µl 
Omniscript Reverse Transcriptase 1 µl 
template RNA (1 µg/µl) 2 µl 
dH2O add 20 µl 
Quantitative real-time PCR was performed using the 7300 Real 
TimePCR System with SDS software 1.3.1 (Applied Biosystems) and a SYBR 
Green PCR Kit (Invitrogen). Reactions were performed in duplicate in a total 
volume of 25 µl with 40 cycles and a combined annealing/elongation at 60 °C 
for one minute. Details for the reaction mix are given below: 
 
 
 
 
 
 
 
After PCR reaction, baselines and threshold values were determined using 
AB 7300 System SDS software. Relative mRNA expression values were 
calculated according to the ∆∆CT approximation method as reported (Pfaffl  
2001) in comparison to a calibrator probe, which was derived from an untreated 
control. Primer sequences used for RT-PCR analysis are given in table 3.1. 
 
Real-time PCR reaction mix Volume / Reaction 
cDNA 5 µl 
primer sense (20 pmol) 2 µl 
primer antisense (20 pmol) 2 µl 
Sybr green master mix 12.5 µl 
dH2O add 25 µl 
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Table 3.1: Primer sequences used for quantitative real-time PCR 
gene orientation sequence in 5´-3´orientation 
AFP sense AGC AAA GCT GCG CTC TCT AC 
antisense AGG GGC TTT CCT CGT GTA AC 
Bax sense CGA GCT GAT CAG AAC CAT CA 
antisense GGT CCC GAA GTA GGA GAG GA 
CD 133 sense CAA ACC CAT GGC CAC CGC GA 
antisense CAC CGT GGC TTT CCC TAT GCC G 
DMBT 1 sense AAT CCC CCA GCA AAG AAA AG 
antisense AGG AAG ACT CCG CCA AAG AT 
DR5 sense GAG GCT GTG AAC GGG ATC C 
antisense GTC GTT TCC GTT TAC CGG AAC C 
E2F1 sense AGA GTG AGC AGC AGC TGG AT 
antisense GGT CCT GGC AGG TCA CAT AG 
F4/80 sense CTT TGG CTA TGG GCT TCC ATC 
antisense GCA AGG AGG ACA GAG TTT ATC GTG 
Fas-L sense GTT TTC TGA GCC GAC CTT TG 
antisense TCA TTG CAC TGG AGG TAT GC 
Fas-R sense TCC AGA AGG ACC TTG GAA AA 
antisense CCT CTC TTC ATG GCT GGA AC 
GAPDH sense TGT TGA AGT CAC AGG AGA CAA CCT 
antisense AAC CTG CCA AGT ATG ATG ACA TCA 
IκB-α sense 
CCA AGT ACC CGG ATA CAG CA 
antisense CTG GCC TCC AAA CAC ACA GT 
IL-6 sense CTT CCA TCC AGT TGC CTT CTT 
antisense AAT TAA GCC TCC GAC TTG TGA AG 
TNF sense AGC ACA GAA AGC ATG ATC CG 
antisense CCC GAA GTT CAG TAG ACA GAA GAG 
p21 sense TTG CAC TCT GGT GTC TGA GC 
antisense TCT GCG CTT GGA GTG ATA GA 
p27  sense GAC AAT CAG GCT GGG TTA GC 
 antisense TCT GTT CTG TTG GCC CTT TT 
TRAIL  sense CCA ACG AGA TGA AGC AGC 
 antisense CCA TCA GTG GAG TCC CAG 
TRAIL-R  sense CCG ACA GAC ATC TAG CAC GA 
 antisense TTA CCG GAA CCA GCA ACT TC 
3.2.5 Isolation and analysis of genomic DNA 
A tail tip biopsy was incubated in 700 µl of lysis buffer (50 mM Tris-HCl 
pH 8, 100 mM EDTA pH 8, 100 mM NaCl, 1 % SDS), supplemented with 35 µl 
proteinase K and incubated at 37 °C, 350 rpm on a thermo mixer overnight. The 
solution was centrifuged at 5000 g and 4 °C for 5 minutes, supernatant 
containing DNA was transferred in a clean microcentifuge tube and precipitated 
with 800 µl isopropanol. After centrifugation at 13000 g (4 °C for 10 minutes), 
the supernatant was discarded and pellet was washed twice with 1 ml of cold 70 
% ethanol. Pellet was dissolved in 50 µl TE buffer (10 mM Tris, pH 7.5 with 1 
mM EDTA) and concentration was determined by measuring OD at 260 nm. A 
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260/280 ratio ≥1.8 was considered high purity. For subsequent PCR 
applications, 1 µl of this DNA was used per 25 µl reaction. 
For determining the Casp8 status of mice, three different PCR reactions 
per sample specific for cre-recombinase, the WT and the floxed Casp8 allele, 
respectively, were performed using the primer pairs as listed in table 3.2. 
Table 3.2: Primer sequences used for genotyping of Casp8∆hepa and 
Casp8f/f mice 
Allele orientation sequence in 5´-3´orientation 
Cre transgene sense CCA CGA CCA AGT GACA GCA AT 
antisense TTC GGA TCA TCA GCT ACA CCA 
WT Casp8 allele sense CAT ACT GGT TGA GAA CAA GAC CTG G 
antisense GCA GAG GTG ACA AGA GGC CAC TG 
Floxed Casp8 allele sense AAC TTC GGC CGG CCA ATA ACT TCG 
antisense AGC AGA AAA ACT TGA AGA AAC TTG G 
 
PCR was performed using Red Taq Mastermix (Sigma) according to 
manufacturer’s instructions with 35 cycles and an annealing temperature of 
56 °C. 
3.2.6 Protein extraction and analysis 
3.2.6.1 Isolation of whole cell protein from liver tissue 
For protein extractions, approximately 1 mg of frozen liver tissue was 
homogenized on ice in 500 µl NP40 buffer. The homogenate was centrifuged 
for 10 minutes at 12.000 rpm and 4 °C. The pellet was resuspended in NP40 
protein extraction buffer, then snap frozen and warmed up few times to break 
the cell membrane and finally centrifuged 10 minutes at 12.000 rpm, 4 °C. 
Aliquots of the supernatants containing whole cell proteins were frozen at 
-80 °C. 
NP40-Buffer final concentration 
Tris HCl 7.5 pH (1 M) 50 mM 
NaCl (5 M) 150 mM 
Nonidet P-40 0.5 % 
Sodium Fluoride 50 mM 
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3.2.6.2 Isolation of nuclear extracts 
A piece of frozen liver was minced in buffer A and incubated for 10 
minutes at 4 °C. After addition of 10% of NP-40, the tube was mixed and 
incubated at 4 °C for 1 minute.  Nuclei were pelleted for 1 minute at 10000 rpm 
and 4 °C and washed with 1 ml of buffer A 2 - 3 times. The pellet was then 
resuspended in buffer C and incubated for 30 minutes on ice, mixed gently, and 
spun down 10 minutes at 10000 rpm (4 °C). The supernatant contained the 
nuclear proteins and was stored at -80 °C before use in EMSA analysis. 
Composition of buffers A and C was as follows: 
 
 
 
 
3.2.6.3 Measurement of protein concentration 
The concentration of whole protein extracts was determined using 
BIO-RAD Protein Assay reagent. This technique is based on the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 
465 nm to 595 nm when binding to protein occurs. According to manufacturer’s 
protocol, proteins and BSA standards with pre-adjusted concentrations were 
measured in a spectrophotometer at OD595. Protein concentrations of samples 
were then calculated by comparison with the OD595 values of the BSA standard 
curve. 
freshly added: 
Sodium Vanadate (100 mM) 1 mM 
DTT (1 M) 1 mM 
PMSF (100 mM) 1 mM 
1 Complete Mini® tablet per 10 ml buffer 
1 PhosSTOP tablet per 10 ml buffer 
Buffer A Buffer C 
HEPES pH 7.6 10 mM HEPES pH 7.8 50 mM 
MgCl2 2 mM KCl 50 mM 
KCl 10 mM NaCl 300 mM 
EDTA 0.1 mM EDTA 0.1 mM 
 + Protease inhibitors 
Glycerol 10% 
 + Protease inhibitors 
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Concentrations of nuclear protein extracts were measured using 
BIO-RAD Dc Protein Assay providing higher sensitivity for low protein 
concentrations. According to manufacturer’s instructions, protein and standard 
were measured in a spectrophotometer at OD750. The OD750 of each sample 
was compared to a standard curve prepared with BSA. 
3.2.7 Western Blot 
Protein samples were separated electrophoretically on 10 %, 12 % or 
15 % denaturing SDS-polyacrylamide gels or on pre-cast 4 – 12 % 
polyacrylamide gels (Invitrogen) according to standard procedures. Gels and 
buffer were prepared as follows (Laemmli, 1970):  
5x Protein loading buffer 1x SDS Running buffer 
Tris-HCl pH 6.8 125 mM Tris-Base 1.25 M 
Glycerol 50% Glycine 2 M 
SDS 5% SDS 1% 
Bromphenol blue 0.025%  
 
 
β-Mercaptoethanol 50 µl per 1 ml loading buffer 
 
Reagent Resolving Gel Stacking Gel 
Percent 10% 12.5% 15% 5% 
dH2O 20 ml 16.4 ml 12.3 ml 13 ml 
1.5M Tris-HCl, pH 8.8 12.5 ml 12.5 ml 12.5 ml - 
0.5M Tris-HCl, pH 6.8 - - - 6.25 ml 
30% Acrylamide 16.5 ml 20.3 ml 24.35 ml 5 ml 
10 % SDS 500 µl 500 µl 500 µl 250 µl 
10 % APS 500 µl 500 µl 500 µl 500 µl 
100 % TEMED 37.5 µl 37.5 µl 37.5 µl 37.5 µl 
 
 20x MOPS running buffer (500 ml) 
Reagent Mass (gram) Final concentration (1x) 
MOPS 104.6  50 mM 
Tris base 60.6 50 mM 
SDS 10.0 3.5 mM 
EDTA 3.0 1 mM 
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10x Transfer Buffer 
Reagent Mass (gram)  
Tris 24.4  
Glycine 112.6  
H2O add 10.0  
For 1x Transfer Buffer: 
Reagent Volume  Final concentration (1x) 
10x Transfer Buffer 100 ml 10 % 
Methanol 200 ml 20 % 
dH2O add 1 l  
 
Briefly, 5x Protein loading buffer was added to each sample in 
appropriate volumes and samples were boiled at 96 °C for 5 minutes before 
loading on the gel. Separation was performed in 1x SDS running buffer at 
50 - 80 V overnight (freshly prepared gels) or in MOPS running buffer at 120 V 
for approximately 2 hours (Invitrogen pre-cast gel system). For immunological 
detection, the separated proteins were transferred from the gel to a 
nitrocellulose membrane (Protran, Whatman) using a wet blotting chamber 
(BIO-RAD) in transfer buffer according to standard procedures. Successful 
protein transfer and equal loading was confirmed by Ponceau Red staining.  
Subsequently, the blotted membrane was blocked for 1.5 hours in PBS-
Tween (Phosphate buffered saline, 0.05 % TWEEN 100) (PBST) supplemented 
with 5 % non-fat dry milk or alternatively in 1x Roti-block (Roth) to block non-
specific antibody-binding sites. The membrane was shortly washed and then 
incubated overnight at 4 °C in PBS with primary antibody at appropriate 
concentrations. The membrane was washed 3 x 5 minutes in PBST and then 
incubated with a secondary horseradish-peroxidase conjugated antibody diluted 
1:5000 in PBST for 1 hour at RT. After incubation, the membrane was washed 
3 x 5 minutes in PBST and then incubated in ECL Substrate (Pierce) for 5 min. 
The membrane was exposed to x-ray film (hyperfilm, Amersham) or a digital 
detection system (LAS, FUJIFILM).  
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3.2.8 Electrophoretic Mobility Shift Assay (EMSA) 
Electrophoretic Mobility Shift Assay (EMSA) was used to determine the 
DNA binding activity of the transcription factor NF-κB. The principle of this 
assay is based on the fact that complexes of proteins (e.g. transcription factors) 
with DNA (e.g. transcription factor binding sites) migrate more slowly in a non-
denaturing polyacrylamide gel compared to free DNA. Briefly, [32P] end-labeled 
DNA fragments containing a NF-κB consensus binding site were incubated 
under native conditions with nuclear protein extracts potentially containing 
activated transcription factors. Binding of activated NF-κB to its consensus 
sequence resulted in formation of slow migrating complexes, which were 
resolved and visualized in non-denaturing polyacrylamide gel electrophoresis. 
Detection of NF-κB in these complexes was carried out by addition of an 
antibody specific for the NF-κB subunit p65 resulting in formation of an 
antibody/NF-κB/DNA super-complex with further retarded migration properties 
(supershift).    
3.2.8.1 Generation of the double-strand DNA probe 
Equal amounts of complementary DNA single strands (each 50 µg) 
encoding NF-κB binding sites (sense:  AGTTGAGGGGACTTTCCCAGGC; 
antisense: GCCTGGGAAAGTCCCCTCAACT) were added to 26 µl 10x 
annealing buffer and H2O at a final volume of 260 µl. After denaturating the 
probe for 5 minutes at 95 °C, the single stranded DNAs were allowed to anneal 
by slowly cooling down to room temperature overnight. The resulting double 
stranded probe could be stored at 4 °C. 
 
 
 
3.2.8.2 Radioactive end-labeling of double-strand DNA probe 
The double-stranded DNA probe was radioactive end-labeled at its 
5´-hydroxyl group by incubating 125 ng of double-stranded probe with 0.4 mCi 
[32P]-γ-ATP and 1 unit T4 polynucleotide kinase (NEB) in 20 µl of T4-Kinase 
10x Annealing buffer final concentration 
Tris/ HCl 1 M, 7.6 pH 200 mM 
MgCl2, 1 M 100 mM 
NaCl, 5 M 500 mM 
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buffer for 1 hour at 37 °C. Labeled probes were purified from free [32P]-γ-ATP 
molecules using Sephadex G-50 Quick-spin-columns according to 
manufacturer’s instructions (Amersham). Efficiency of the labeling and the 
radioactivity was determined using a β-scintillation counter. 
3.2.8.3 Gel shift analysis 
EMSA reactions were carried out in a total volume of 20 µl. For each 
reaction 5 µg of nuclear protein extract was mixed with 4 µl 5x binding buffer (1 
M HEPES, 0.5 M MgCl2, 1 M KCl), 2 µl 10x proteinase inhibitor cocktail 
(1 M DTT, 0.1 M Pefablock, 200 µl Aprotinin), 1 µl Poly dI:dC (1 µg/ µl), 1 µl 
BSA (10 µg/ µl in dH2O) and P32-labelled oligonucleotide (30000 cpm per 
reaction). As control, a reaction mix without protein (free probe) was applied. 
The samples were incubated 30 minutes on ice. For super-shift-assays, 1 µl of 
specific p65 antibody (Santa Cruz) was added to a sample and incubated for 
another 30 minutes on ice. The reaction was stopped with 2 µl loading buffer 
containing 20 % Ficoll. Samples were loaded on a non-denaturating 
polyacrylamide gel (5 %) and separated at 300 volt and 4 °C for approximately 
3 hours in 0.25 X TBE running buffer (22.5 mM Tris, 22.25 mM H3BO3, 0.5 mM 
EDTA). The gel was fixed for 30 minutes in 20 % methanol/10 % acetic acid, 
transferred to a Whatman filter, dried under vacuum and exposed at -80 °C on 
x-ray film.  
3.2.9 Measurement of enzymatic Caspase-3 activity 
Caspase-3 is a key effector caspase involved in extrinsic and intrinsic 
apoptosis. Enzymatic caspase-3 activity was determined using an artificial 
Caspase-3 specific substrate (DEVD) linked to a fluorochrome (AFC). Active 
Caspase-3 within protein lysates specifically cleaved the substrate DEVD 
between D and AFC, thus releasing free AFC which was quantified by UV 
spectrofluorometry. Therefore, AFC-mediated fluorescence was proportional to 
Caspase-3 activity. For isolation of native protein extracts, 1 mg of frozen liver 
tissue was homogenized on ice in 500 µl of lysis buffer containing 10 mM 
HEPES pH 7.4, 0.1 % CHAPS, 2 mM EDTA, 5 mM DTT, 1 mM PEFA-Block and 
protease inhibitors (Complete Mini®, Roche). The homogenate was centrifuged 
for 10 minutes at 12.000 rpm and 4 °C. Supernatant was transferred into new 
tube and protein concentration was determined. Samples were shock frozen in 
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liquid nitrogen and stored at -80 °C. For each reaction, 12.5 µl protein extract 
(typically 1 µg/ µl) were mixed with 487.5 µl reaction buffer containing 10 mM 
PIPES, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT and 25 µM DEVD-AFC. The 
reaction mix was pipetted in duplicate (200 µl/well) into a 96-well-cellstar plate 
and incubated at 37 °C with shaking for 1 hour. Subsequently, AFC-release was 
measured in a fluorospectrometer (Biotec) with an extinction-wavelength of 390 
nm and an emission-wavelength of 510 nm after 1 and 2 hours, respectively. 
The specific alteration of fluorescence per hour was determined and calculated 
as fold induction in comparison to untreated control samples. 
3.2.10 p65 - Immunohistochemistry     
Paraffin embedded sections were deparaffinised and rehydrated with 
xylene and decreasing percentages of ethanol. Antigen retrieval was performed 
by boiling sections in sodium citrate buffer for 6 minutes in a microwave. After 
cooling for 15 minutes, sections were rinsed in running tap water and 
endogenous peroxidases were quenched for 15 minutes. Sections were 
washed under running water, and subsequently washed for 5 minutes in PBS. 
Following blocking with biotin blocking reagent for 15 minutes and with Avidin D 
blocking reagent for 15 minutes, sections were blocked in PBT (PBS, 0.1 % 
BSA, 0.2 % TritonX-100) and then incubated overnight with p65-antibody 
(Santa Cruz) at 4 °C in a humid atmosphere. Slides were washed twice with 
PBS and secondary antibody (anti-mouse, HRP linked (Cell Signaling 
Technology)) was applied for 1 hour at room temperature in a humidifying box. 
In parallel, the HRP-ABC solution (VECTORSTAIN ABC reagent: 7,5 µl solution 
A and 7,5 µl solution B in 500 µl 1% BSA/PBS) was prepared and incubated at 
least 30 minutes at room temperature before it was applied to the slides. 
Sections were rinsed twice in PBS and HRP-ABC solution was applied for 1 
hour at room temperature in a humidified box. After washing twice in PBS, the 
signal was developed with DAB and counterstained with hematoxylin. 
Dehydration was performed with increasing percentages of ethanol and xylene, 
mounted with Roti-histokit and visualized by bright field microscopy or 
alternatively by using a Leica Z16 APO macroscope with DISCUS software (Fa. 
Carl H. Hilgers).  
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3.2.11 Immunofluorescence 
Cryosections (5 µm) from mouse livers were fixed with 4 % 
paraformaldehyde for 15 minutes and rehydrated with PBS for 15 minutes. All 
subsequent steps were carried out at room temperature unless otherwise 
indicated in a humid light tight box to prevent drying and fading. PBS containing 
5 % goat serum and 0.3 % Triton was used for blocking for one hour, followed 
by an overnight incubation with primary antibody in blocking solution at 
optimized dilutions at 4 °C. Slides were washed with PBS for 15 minutes and 
incubated with secondary, fluorochrome-conjugated antibody, diluted 1:200, in 
PBS for one hour at RT. Nuclei were counterstained with DAPI in mounting 
medium. Expression was visualized and documented by fluorescence 
microscopy (Zeiss). 
For monitoring CK-19 expression, cryosections were fixed with Acetone 
for 10 minutes at -20 °C. Tissue sections were blocked with PBS containing 5 % 
goat serum and 0.3 % Triton for one hour at RT, followed by probing with a 
CK-19 antibody (diluted 1:200 in TBST) over night at RT in a humidified 
chamber. Slides were washed with TBST and probed with a fluorochrome-
conjugated secondary antibody (diluted 1:200 in TBST, 1 % goat serum). 
Sections were incubated for 60 minutes, washed three times in TBST and 
mounted with mounting medium containing DAPI.  
TUNEL (TdT-mediated dUTP nick end labeling) is an established method 
for in situ labeling of DNA strand brakes that occur early during apoptosis. 
Terminal deoxynucleotidyl transferase (TdT) is used to introduce labeled 
nucleotides into partially degraded DNA. For TUNEL analysis, an In Situ Cell 
Death Detection Kit (Roche) was used. Liver cryosections were fixed with 4 % 
paraformaldehyde for 20 minutes and rehydrated with PBS for 30 minutes. 
Sections were treated with 3 % H2O2 in methanol for 10 minutes, and then 
permeabilized with 0.1 % Triton, 0.1 % Na-citrate for 2 minutes at 4 °C. Slides 
were washed with PBS and stained with TUNEL mix according to 
manufacturer’s instructions (Roche) in a humidified chamber overnight at 4 °C. 
After washing with PBS stained sections were mounted with DAPI mounting 
medium and analyzed by fluorescence microscopy.  
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4 Results 
4.1 Experimental design of the study  
Resistance to apoptosis is a hallmark of cancer. As Caspase-8 (Casp8) 
is the apical caspase in the extrinsic (e.g. death-receptor-mediated) apoptotic 
pathway, genetic inactivation of Casp8 in hepatocytes (Casp8∆hepa) was 
expected to completely block extrinsic apoptosis in parenchymal cells of the 
liver.  
To investigate the effects of Casp8-deficiency for development of liver 
cancer, the well-established Diethylnitrosamine (DEN) model of chemically 
induced hepatocarcinogenesis was applied (Bralet et al. 2002). Basically, two 
different experimental approaches were used to determine the role of Casp8 for 
HCC development.  
In a high dose DEN-model, 6-8 week old male Casp8∆hepa mice and 
Casp8f/f controls were given 200mg/ kg DEN to induce an acute injury and 
genotoxic damage (Janani et al. 2008). In these mice, the mode of liver injury 
and the kinetics of liver regeneration were studied for up to 96 hours to 
determine potential functions of Casp8 for elimination of premalignant 
hepatocytes and cell proliferation. 
In a low dose DEN-model, two weeks old Casp8∆hepa and Casp8f/f mice 
were injected with a single dose of 25 mg /kg DEN which usually triggers 
hepatocarcinogenesis (Diwan & Meier 1976). Cohort of mice were sacrificed 24 
weeks and 40 weeks after DEN treatment and analyzed for markers of tumor 
development in the liver. These studies included macroscopic inspections 
(determination of tumor size and number), histological analyzes and molecular 
expression studies on cell cycle related genes, oncogenes and pro-apoptotic 
factors.  
4.2 Loss of Casp8 in hepatocytes does not affect the acute 
response to DEN-mediated liver injury  
In order to determine the role of Casp8 for the acute response towards 
cancerogenic stimuli, 6 – 8 weeks old male Casp8∆hepa mice and Casp8f/f 
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controls were injected with 200mg/ kg DEN. Previous reports demonstrated that 
these high doses of DEN trigger acute liver injury, accumulation of DNA-
damage and a compensatory proliferation (Naugler et al. 2007). The DEN-
response was monitored over a period of 96 hours with a minimum of three 
animals per time point and condition. The precise composition of the mouse 
cohorts used for these experiments is given in table 4.1.  
Table 4.1: Cohort size and time points used for measurements of acute response in the liver 
following DEN treatment. 
Alanine-aminotransferase (ALT) and Aspartat-Aminotransferase (AST) 
are both liver enzymes used as well established standard indicators for liver 
injury. ALT is most specific for the liver whereas AST is also found in heart and 
muscles. During liver injury, the activity of both enzymes in the serum is 
increased as AST and ALT are released upon liver cell death (Malhi et al. 
2010). 
Following DEN-treatment, both Casp8f/f and Casp8∆hepa mice showed a 
strong increase of AST and ALT levels 48 hours after stimulation which was not 
significantly different between the groups (Figure 4.1). At later time points after 
treatment (72 - 96 hours post DEN) a tendency towards higher transaminase 
levels in Casp8∆hepa mice was observed. However, these differences did not 
reach statistical significance. Thus, genetic inactivation of Casp8 does not 
protect from overall DEN-induced acute liver injury.  
Time point 
after DEN 
treatment 
Number of animals in 
control group  (Casp8f/f) 
Number of animals in 
knockout group  (Casp8∆hepa) 
0h 9  8  
24h 3  3  
48h 4  3  
72h 3  3  
96h 3  3  
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Figure 4.1: Transaminase activation after DEN treatment. Casp8f/f  and Casp8∆hepa mice 
were subjected to single injection with DEN (200mg/ kg) at the age of 6 - 8 weeks and sacrificed 
after 24, 48, 72 and 96 hours respectively. Blood was taken every 24 hours and serum was 
analyzed for AST and ALT activity levels in units per liter (U/L). Data is shown as a scatter plot; 
each dot represents a serum value of one individual mouse. n.s.: not significant. 
The cytokines Interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) 
are important pro-inflammatory mediators in the liver and are secreted almost 
immediately after acute liver injury especially from Kupffer cells which are 
considered the resident macrophages of the liver (Malhi & Gores 2008). It was 
recently suggested that IL-6 and TNF might be key factors for 
hepatocarcinogenesis induced by DEN or obesity (Naugler & Karin 2008, Sun & 
Karin 2008, Park et al. 2010). Therefore, mRNA expression levels of IL-6 and 
TNF were determined in livers from DEN-treated Casp8f/f and Casp8∆hepa mice 
48 hours after treatment (Figure 4.2) which reflected the state of maximal injury 
(compare Figure 4.1). In good agreement with previous studies, both IL-6 and 
TNF were substantially induced by DEN although without significant differences 
between the groups. This indicates that TNF/IL-6 induction is not dependent on 
functional Casp8. Of notice, untreated Casp8∆hepa mice revealed significantly 
increased TNF expression levels confirming that loss of Casp8 induces a 
moderate inflammation in the liver as reported recently (Liedtke et al. 2011). 
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Figure 4.2: Cytokine expression after DEN-mediated liver injury. Casp8f/f and Casp8∆hepa 
mice were subjected to single injection with DEN (200mg/ kg) at the age of 6 – 8 weeks and 
sacrificed after 48 hours respectively. Gene expression was normalized via GAPDH expression 
levels. Data were calculated as fold induction in comparison to untreated Casp8f/f control-mice.  
The major known function of Casp8 is the induction of extrinsic pro-
apoptotic signals cumulating in cell death. The main focus of this study was to 
evaluate if Casp8-driven apoptosis might be relevant to prevent liver tumors. 
Therefore, TUNEL stainings were performed on liver sections from DEN-treated 
Casp8f/f- and Casp8∆hepa-mice at several time points after stimulation. 
Surprisingly, at none of the time points investigated, Casp8∆hepa mice showed a 
decrease of TUNEL positive cells (Figure 4.3 A, B). In contrast, 72 hours after 
treatment, Casp8∆hepa livers showed even significantly increased TUNEL 
staining. These unexpected data indicated that Casp8 is not essential for DEN-
induced liver cell death and hinted at alternative cell death pathways (e.g. 
necrosis, intrinsic apoptosis) that might be more relevant in this model. 
It has been reported that in some cases TUNEL staining may also label 
necrotic cells. To clearly distinguish apoptotic cell death from necrosis, the 
enzymatic activity of caspase-3 was determined after DEN treatment. Caspase-
3 is an executioner caspase, which acts downstream of intrinsic and extrinsic 
apoptotic signaling pathways. Thus, caspase-3 activation is a highly specific 
indicator of apoptosis. Basically, determination of caspase-3 activity confirmed 
the data generated by TUNEL analysis. In both Casp8f/f and Casp8∆hepa mice, 
caspase-3 activity was substantially up-regulated 48 hours after treatment and 
still elevated 72 hours post DEN (Figure 4.3 C). However, there was not any 
significant difference between the groups at any investigated time point. These 
data clearly demonstrated that DEN induces at least some apoptosis which is 
independent of Casp8 and most likely involves intrinsic signaling pathways. 
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Figure 4.3: TUNEL Immunofluorescence (A) and Caspase 3 assay (C) after DEN-induced 
liver injury. A. Casp8f/f- and Casp8∆hepa-mice were injected with DEN (200mg/ kg) at the age of 
6 - 8 weeks and sacrificed after 24, 48, 72 and 96 hours, respectively. Liver cryosections were 
stained with the TUNEL method; apoptotic cells are stained in green; total cells were counter 
stained with DAPI (blue). B. Quantification of TUNEL-positive cells shown in A. For each mouse, 
three independent magnification fields were analyzed. *: p<0.05; n.s: not significant. C. Caspase 
activity was measured in 48 and 72 hours DEN treated mice as substrate turnover of a 
fluorescence substrate and is indicated as Arbitrary Fluorescence Unit (AFU). n.s.: not 
significant. 
4.2.1 Lack of Casp8 accelerates onset of hepatic cell proliferation after 
DEN treatment 
One requirement of tumorigenesis is an increased proliferation capacity 
(Malumbres & Barbacid 2009). Of notice, one important trigger of proliferative 
response could be cell loss due to apoptosis or necrosis. Although the previous 
experiments did not show significant differences of apoptosis in Casp8∆hepa and 
Casp8f/f mice, recent data suggested an influence of Casp8 on cell cycle 
regulation and NF-κB-activation (Maelfait & Beyaert 2008). Therefore, liver 
sections of DEN-treated Casp8∆hepa and Casp8f/f mice were stained for the 
general proliferation marker Ki-67 to visualize and quantify cells in the active 
phase of the cell cycle.  
Interestingly, untreated Casp8∆hepa mice already revealed a slight but 
significant increase in proliferating liver cells (Figure 4.5) suggesting that loss of 
Casp8 triggers moderate basal proliferation in the liver. Moreover, the data 
showed a significant (p = 0.002) higher amount of proliferating cells in 
Casp8∆hepa in comparison to Casp8f/f mice 24 hours after DEN treatment, 
whereas the proliferative response in these mice was similar to controls at later 
time points. Thus, Casp8∆hepa-mice seem to be pre-activated for hepatic cell 
proliferation and show an accelerated proliferative response towards toxic liver 
injury.  
A 
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Figure 4.4: Ki-67-Immunofluorescence after DEN-induced liver injury. Casp8f/f and 
Casp8∆hepa mice were injected with DEN (200mg/ kg) at the age of 6 - 8 weeks and sacrificed 
after 24, 48, 72 and 96 hours, respectively. A. Quantification of Ki-67-positive cells shown in B. 
The percentage of TUNEL-positive cells is indicated on the y-axis. For each mouse, three 
independent magnification fields were analyzed. **: p<0.01;*: p<0.05; n.s: not significant. B. 
Liver cryosections were stained with a fluorescence-labeled Ki67-antibody; cells in active cell 
cycle are stained in green; total cells were counter stained with DAPI (blue).  
It was recently shown that DEN-induced HCC development depends on 
activation of Jun N-terminal kinase 1 (JNK1) (Hui et al. 2008) which belongs to 
an important family of stress-activated mitogen activated kinases (MAPK). The 
most prominent substrate of JNK is the transcription factor cJun. Together with 
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members of the Fos family, cJun forms the activating protein 1 (AP-1) which is 
important for activation of cell cycle controlling genes and thus for induction of 
cell proliferation (Eferl & Wagner 2003). Therefore, aberrant JNK/cJun response 
could have an impact on tumor incidence. In this context, recent data showed a 
premature up-regulation of cJun in Casp8∆hepa mice after 2/3-hepatectomy 
resulting in accelerated onset of hepatocyte proliferation (Freimuth et al., 
unpublished data).  
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Ti
m
e 
af
te
r 
D
EN
 
tr
ea
tm
e
n
t CTRL 
96 h 
72 h 
24 h 
48 h 
Results 
36 
 
Figure 4.5: Phosphorylation and activation of cJun after DEN-induced liver injury. Casp8f/f 
and Casp8∆hepa mice were injected with DEN (200mg/ kg) at the age of 6 - 8 weeks and 
sacrificed after 24, 48, 72 and 96 hours, respectively. Liver cryosections were stained for 
phosphorylated cJun using and fluorescence-labeled antibody; p-Jun positive cells are stained 
in green; total cells were counter stained with DAPI (blue).  
In the present study the kinetics of cJun-activation after DEN induced 
liver injury were determined semi-quantitatively by performing 
immunofluorescence stainings for phosphorylated cJun on liver cryosections at 
distinct time points after DEN treatment (Figure 4.6). These measurements 
revealed a strong cJun-phosphorylation with two maxima after 24 and 72 hours, 
respectively. However, the staining pattern did not show substantial differences 
between Casp8∆hepa and Casp8f/f mice. These data suggests that Casp8 does 
not have a major impact on cJun activation at least in the DEN model.  
4.2.2  Activation of the cell cycle inhibitor p21 after DEN treatment is 
independent of Casp8  
With initiation of the present study, it was hypothesized that loss of 
Casp8 may affect the compensatory proliferation after acute DEN-induced liver 
injury. To complete these measurements, the induction of the cell cycle inhibitor 
p21 was also studied under these conditions. p21 is a cyclin dependent kinase 
inhibitor which influences cellular proliferation, differentiation and senescence 
as well as DNA damage repair (Abbas & Dutta 2009). Importantly, p21 down-
regulation was shown to be a key event for efficient HCC development in the 
DEN model (Hui et al. 2008).  Therefore, mRNA expression of p21 after DEN 
delivery was investigated in Casp8∆hepa mice and compared to Casp8f/f control 
animals.  
The data demonstrate a remarkable DEN-induced up-regulation of p21-
expression in both Casp8f/f and in Casp8∆hepa mice and did not show significant 
differences between the groups (Figure 4.7). In conclusion, the cyclin 
dependent kinase inhibitor p21 is substantially up-regulated in the acute phase 
of DEN-induced injury. However, this regulation is completely independent of 
Casp8 in this context.  
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Figure 4.6: Gene-expression analysis of p21 after DEN-mediated liver injury. Casp8f/f and 
Casp8∆hepa mice were subjected to single injection with DEN (200mg/ kg) at the age of 6 – 8 
weeks and sacrificed after 48 hours respectively. Gene expression of p21 was determined by 
quantitative real-time PCR and normalized via GAPDH expression levels. Data were calculated 
as fold induction in comparison to untreated Casp8f/f control-mice.  
In summary, the previous data hint at an unexpected moderate effect of 
Casp8 on the immediate response towards DEN in the liver. Casp8 deficiency 
results in a slightly accelerated onset of compensatory proliferation but 
otherwise does not have an impact on inflammation and apoptosis.  
4.3.1 Loss of Casp8 does not affect tumor initiation in the liver  
Application of DEN at low dose to juvenile mice at the age of 2 weeks is 
a well-established animal model of hepatocarcinogenesis (Diwan & Meier 
1976). Under these conditions, WT mice develop liver dysplasia within 24 
weeks which further progress to solid tumor nodules in a total time of 
approximately 40 weeks (Bralet et al. 2002). Under these conditions, dysplastic 
nodules can be recognized in liver tissue sections as well-defined areas of cell 
formations which are frequently encapsulated. 
To investigate, if Casp8 acts as a tumor suppressor, cohorts of DEN-
treated Casp8f/f and Casp8∆hepa mice were sacrificed 24 weeks after tumor 
induction and histologically investigated for formation of dysplastic liver lesions. 
For this approach, HE stained liver sections were analyzed with a software-
based imaging system (Discus, Fa. Carl H. Hilgers, Königswinter, Germany) 
that allowed the quantification of dysplastic tissue areas within the liver section. 
The data is shown in Figure 4.8. Initial analysis suggested a substantial 
appearance of dysplastic lesions in both Casp8f/f and Casp8∆hepa liver (Figure 
p21 expression
0
10
20
30
50
10
0
15
0
20
0 Casp8f/f
Casp8∆hepa
0 h 48 h
fo
ld
 
in
du
ct
io
n
Results 
38 
 
4.8 A). A more precise classification of these lesions by size revealed a similar 
frequency of small dysplastic areas (<50.000 µm2) but also of medium size 
lesions (50.000-200.000 µm2). Interestingly, Casp8∆hepa livers showed a higher 
tendency to form large liver lesions >200.000 µm2 compared to Casp8f/f controls 
(Figure 4.8 B), although at this stage these differences were not statistically 
significant. However, the cumulative dysplastic liver areas in both groups were 
not significantly different. As this stage (24 weeks after DEN treatment) was 
considered the initiation phase of hepatocarcinogenesis, it was concluded from 
this data that Casp8 does not protect from tumor initiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Determination of dysplastic tissue area in liver of DEN treated mice. Casp8f/f- 
and Casp8∆hepa-mice were injected with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed 
after 24 weeks. A. HE staining of representative liver sections 24 weeks after DEN-induced 
tumorigenesis. Pre-cancerogenous liver lesions are encircled. (B, C). HE stained liver sections 
from every DEN-treated animal were analyzed using Discus-Imaging software. Number and size 
of dysplastic tissue area was determined. B. Detected dysplastic nodules were categorized by 
size and compared between Casp8f/f- and Casp8∆hepa-mice. C. The cumulative size of dysplastic 
nodules in liver sections was determined and calculated as dysplasia:total-tissue area ratio for 
every DEN-treated mouse.  
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4.3.2 Loss of Casp8 triggers enhanced tumor progression 
The previous findings suggested that loss of Casp8 does not affect tumor 
initiation in the DEN model. However, these unexpected findings did not 
exclude the possibility that the inactivation of Casp8 could have an impact on 
tumor growth. To test this hypothesis, cohorts of Casp8f/f and Casp8∆hepa-mice 
were sacrificed 40 weeks after DEN-injection. Livers were extracted and visible 
tumor nodules were quantified and compared.  
 
 
 
 
 
 
 
 
 
. 
Figure 4.8: Casp8 inhibits advanced tumor progression. Casp8f/f and Casp8∆hepa mice were 
injected with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 40 weeks. Livers were 
extracted and macroscopic tumor nodules (white arrows) were quantified and analyzed for size. 
A. Representative image of a Casp8f/f liver displaying typically 1 - 2 nodules. B. Representative 
image of a Casp8∆hepa liver with frequent appearance of tumors. C. Tumor frequency in Casp8f/f 
and Casp8∆hepa mice. Each dot represents the number of tumor nodules found in one individual 
mouse. D. The size (mm diameter) of the largest tumor in each animal is indicated and serves 
as a measurement of overall tumor growth potential. E. The cumulative tumor diameter for each 
Casp8f/f and Casp8∆hepa mouse was calculated.  *: p<0.05. 
At this time point, macroscopically visible tumor nodules were detectable 
in both Casp8f/f and Casp8∆hepa livers (Figure 4.8 A - B). Casp8f/f livers 
displayed an average tumor number of 1.6 per liver (SD: ± 3.2, Figure 4.9 C) 
and a cumulative tumor diameter of 3.1 mm/animal (SD: ± 6.8, Figure 4.9 D -
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 E). Interestingly, Casp8∆hepa mice revealed a significantly increased number of 
tumor nodules per liver (5.6; SD: ± 8.9), which were also significantly enlarged 
in total and cumulative size (12.0 mm; SD: ± 18.2) compared to controls (Figure 
4.9 C - E). Accordingly, this data demonstrates that loss of Casp8 results in 
enhanced tumor progression especially between 24 - 40 weeks after tumor 
induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Loss of Casp8 results in enhanced formation of dysplastic liver lesions 40 
weeks after DEN-mediated tumor induction:  Casp8f/f and Casp8∆hepa mice were injected with 
DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 40 weeks. Liver sections were 
stained with HE and analyzed microscopically. A. Representative HE staining showing 
moderate dysplasia in Casp8f/f mice (encircled, left) and large dysplastic lesions in Casp8∆hepa 
mice (right, partially encircled). (B, C). HE stained liver sections from every DEN-treated animal 
were analyzed using Discus-Imaging software. Number and size of dysplastic tissue area was 
determined. B. Detected dysplastic nodules were categorized by size and compared between 
Casp8f/f and Casp8∆hepa mice. C. The cumulative size of dysplastic nodules in liver sections was 
determined and calculated as dysplasia:total-tissue area ratio for every DEN-treated mouse. 
*: p<0.05. 
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To further confirm these results, liver sections were stained with HE and 
analyzed for number and size of dysplastic nodules as already described in 
4.3.1. In sharp contrast to the findings at early tumor initiation (compare Figure 
4.8), the liver histology in Casp8∆hepa mice revealed significantly more dysplasia 
compared to Casp8f/f controls (Figure  4.10 A - B). A more detailed analysis of 
dysplastic foci by size demonstrated that Casp8∆hepa liver comprised less small-
sized foci but significantly more large-sized lesions compared to control mice 
(Figure 4.10 C). In summary, this data confirms that ablation of Casp8 triggers 
tumor growth selectively during advanced hepatocarcinogenesis.  
4.3.3 DEN-induced hepatocarcinogenesis is independent of Casp8-
mediated extrinsic apoptosis  
Casp8 is the apical caspase involved in extrinsic, death-receptor 
mediated apoptosis (Salvesen 1999). Accordingly, it was hypothesized that 
ablation of Casp8 would affect DEN-driven hepatocarcinogenesis if extrinsic 
apoptosis is involved in this process. However, the previous experiments 
suggested that Casp8 is not relevant for the immediate response towards to 
DEN-induced liver injury as no differences in apoptosis levels were found 
between Casp8∆hepa mice and controls. To investigate, if extrinsic apoptosis 
plays a role for tumor initiation or tumor progression, TUNEL-analysis was 
performed with liver sections derived from DEN-treated Casp8f/f and Casp8∆hepa 
mice 24 and 40 weeks after treatment, respectively.  
The results are shown in Figure 4.10. Although the number of TUNEL-
positive cells slightly increased in both in Casp8f/f and Casp8∆hepa mice 
throughout tumor progression, significant differences between the groups could 
not be detected (Figure 4.10 B). Thus, Casp8 mediated apoptosis does not play 
a major role for DEN-induced liver cancer development. 
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Figure 4.10: TUNEL immunofluorescence after DEN-induced liver injury. A. Casp8f/f and 
Casp8∆hepa mice were injected with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 
24 and 40 weeks, respectively. Liver cryosections were subjected to TUNEL analysis; apoptotic 
cells are stained in green; total cells were counter stained with DAPI (blue). B. Quantification of 
TUNEL-positive cells shown in A. For each mouse, three independent magnification fields were 
analyzed.  
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To further support the previous finding that apoptosis does not play a 
major role in DEN-induced hepatocarcinogenesis in Casp8f/f mice or Casp8∆hepa 
animals, the gene expression of pro-apoptotic mediators in early and advanced 
liver cancer was determined by quantitative real-time PCR. For this approach, 
six well characterized pro-apoptotic genes were selected: Fas, TRAIL, their 
cognate receptors Fas-R and TRAIL-R2 and the intrinsic apoptosis genes Bax 
and Noxa, respectively. 
Fas-ligand (Fas) is a type II transmembrane protein and a prototypical 
member of the tumor necrosis factor (TNF) family (Nagata & Golstein 1995). 
Binding of Fas to its receptor usually induces extrinsic apoptosis e.g. in 
hepatocytes in a Casp8-dependent manner (Timmer et al. 2002). Similarly 
TRAIL is also capable of inducing death-receptor mediated apoptosis by binding 
its cognate receptors TRAIL-R1 (Death Receptor 4 (DR-4)) or TRAIL-R2 (DR-
5), respectively (Malhi et al. 2006). Of notice, in contrast to human, mice do not 
express TRAIL-R1 but a receptor similar to human’s TRAIL-R2 (Wu et al. 1999). 
Moreover, it has been demonstrated in several studies that TRAIL receptor 
expression is regulated by the tumor suppressor p53 e.g. following genotoxic 
stress (Wu et al. 1997) and thus is induced in tumor cells or in hepatocytes 
during chronic inflammation. Bax and Noxa belong to the pro-apoptotic 
members of the Bcl-2 family members and are therefore involved in controlling 
intrinsic apoptosis and the mitochondrial permeability transition (Hassan et al. 
2008). 
The results of the measurements are shown in Figure 4.11. Interestingly, 
none of the investigated genes was up-regulated in Casp8f/f mice at tumor 
initiation (24 weeks after DEN) or during advanced tumor progression further 
supporting the idea that neither extrinsic nor intrinsic apoptosis plays a major 
role in DEN-induced hepatocarcinogenesis. However, a sub-population of 
Casp8∆hepa mice revealed an increased expression of Fas 24 weeks after DEN 
treatment (Figure 4.11 A). Although the overall Fas expression at this time point 
was not significantly different from the control group, these data suggest that 
loss of Casp8 in hepatocytes could prime the liver for enhanced infiltration of 
Fas-expressing immune cells. In line with these findings, Casp8∆hepa livers also 
showed significantly higher expression of Fas-receptor 24 weeks after DEN 
treatment (Figure 4.11 B).  
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Figure 4.11: Gene expression analysis of pro-apoptotic genes after DEN-mediated tumor 
induction. Casp8f/f and Casp8∆hepa mice were subjected to single injection with DEN 
(25 mg/ kg) at the age of 2 weeks and sacrificed after 24 and 40 weeks, respectively. Gene 
expression was determined by quantitative real-time PCR and normalized via GAPDH 
expression levels. Data were calculated as fold induction in comparison to untreated Casp8f/f 
control-mice. Each dot represents the gene expression of one individual mouse. A. Expression 
of Fas ligand (Fas). B. Expression of Fas-receptor. C. Expression of TRAIL ligand. D. 
Expression of TRAIL-receptor 5. E. Expression of Bax. F. Expression of Noxa. *: p<0.05; ns: not 
significant. 
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Accordingly, the Fas signaling cascade is activated at least in a sub-
population of Casp8∆hepa mice after DEN challenge, although the signals cannot 
induce apoptosis due to the lack of Casp8. It is therefore possible that these 
signals may activate alternative pathways (e.g. NF-κB) in the absence of 
Casp8. This aspect will be further addressed in the discussion.  
However, in good agreement with the data derived from the TUNEL 
experiments, significant de-regulation of TRAIL/TRAIL-R5, Bax or Noxa was not 
observed in Casp8∆hepa livers at any time point investigated (Figure 4.11 C - F) 
which was very similar to the findings obtained from WT controls. In summary, 
the initial hypothesis that enhanced tumor progression in Casp8∆hepa mice 
occurs due to reduced apoptosis of premalignant cells could not be confirmed 
since apoptosis seems to play only a minimal role in the DEN model. 
4.3.4 Determination of liver cell proliferation in Casp8∆hepa mice after 
DEN-treatment 
Uncontrolled excessive cell proliferation is a hallmark of cancer 
(Hanahan & Weinberg 2000). Due to the increased tumor progression in 
Casp8∆hepa mice, a higher amount of proliferating cells in the liver was expected 
in these mice 40 weeks after DEN-treatment. In agreement with this idea, Ki67-
staining indicated more hepatocyte proliferation in Casp8∆hepa mice at 40 weeks 
after DEN-injection compared to Casp8f/f-controls (Figure 4.12), although the 
differences were not statistically significant (p = 0.08). Moreover, the results of 
the Ki67-staining confirmed the previous histological analysis in 24 week old 
mice (compare Figure 4.8)  in which no differences in tumor initiation were 
observed between Casp8f/f  and Casp8∆hepa mice 24 weeks after DEN-
treatment. Therefore, the data suggests that a slight increase in overall 
hepatocyte proliferation in Casp8∆hepa mice occurring between 24 and 40 weeks 
after DEN-treatment might be sufficient to explain enhanced tumor progression. 
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Figure 4.12: Ki67-immunofluorescence after DEN-treatment. Casp8f/f- and Casp8∆hepa-mice 
were injected with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 24 and 40 weeks, 
respectively. A. Liver cryosections were stained with a Ki67-antibody; cells in active cell cycle 
are stained in green; total cells were counter stained with DAPI (blue). B. Quantification of Ki67-
positive cells shown in A. For each mouse, three independent magnification fields were 
analyzed. *: p<0.05; ns: not significant. 
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Recent data showed that loss of Casp8 triggered accelerated and 
prolonged onset of the JNK/c-Jun-pathway after 2/3-hepatectomy, which 
resulted in premature induction of the cell cycle and liver regeneration (Julia 
Freimuth, unpublished data). In order to explain the enhanced tumor 
progression in Casp8∆hepa-mice observed in the present study, it was 
speculated that constitutive activation of the JNK/c-Jun-pathway could 
contribute to these findings. Therefore, c-Jun phosphorylation was investigated 
in Casp8f/f and Casp8∆hepa mice 24 and 40 week after DEN-treatment by 
immunofluorescence staining using a phosphorylation-specific antibody.  
 Casp8f/f Casp8∆hepa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Determination of cJun phosphorylation after DEN-mediated tumor induction: 
Casp8f/f and Casp8∆hepa mice were injected with DEN (25 mg/ kg) at the age of 2 weeks and 
sacrificed after 24 and 40 weeks, respectively. Liver cryosections were stained with an antibody 
selectively detecting phosphorylated cJun; p-Jun-positive cells are stained in green; total cells 
were counter stained with DAPI (blue).  
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Of note, untreated Casp8∆hepa control mice revealed some basal cJun 
activation which was not detected in the Casp8f/f counterpart (Figure 4.13). 
However, this is in good agreement with the recent observation that Casp8∆hepa 
mice develop moderate spontaneous liver inflammation (Liedtke et al. 2011). 
Regarding tumor initiation (24 weeks post DEN) and advanced tumor 
progression (40 weeks post DEN) substantial differences in cJun activation 
were not observed. Nonetheless, focal concentrations of p-cJun positive cells 
were observed in assumed dysplastic liver lesions or inflammatory infiltrates 40 
weeks after DEN which were moderate or large in Casp8f/f mice and small in 
Casp8∆hepa animals (Figure 4.13). Due to the high variation of these staining 
patterns, this data did not allow any conclusion regarding potential interactions 
between Casp8 and the JNK/cJun-pathway in the DEN model. 
4.3.5 Determination of the inflammatory response in Casp8∆hepa mice 
in DEN-induced hepatocarcinogenesis 
Several studies suggested that hepatocellular carcinoma mostly 
develops in a pro-inflammatory environment (Karin et al. 2006 – 2007). 
Although the DEN model is typically not associated with chronic inflammation, 
recent reports demonstrated that pro-inflammatory mediators such as IL-6 and 
TNF play a crucial role in DEN-induced hepatocarcinogenesis (Naugler & Karin 
2008).  
To test, if Casp8 is involved in this process, mRNA-expression levels of 
IL-6 and TNF were determined in Casp8f/f and Casp8∆hepa mice 24 and 40 
weeks after DEN treatment, respectively. In agreement with previous studies, 
IL-6 expression was slightly up-regulated during the course of tumor 
development, while no significant differences between the control group and 
Casp8∆hepa mice could be observed (Figure 4.14 A., left panel). Similarly, TNF 
expression levels in both groups were identical 24 - 40 weeks after DEN 
treatment, whereas basal TNF expression was significantly increased in 
Casp8∆hepa mice as reported recently (Liedtke et al. 2011). However, a more 
detailed analysis of IL-6 expression in the Casp8∆hepa cohort 40 weeks post 
DEN identified a sub-population of animals (n = 5) with strongly elevated IL-6 
levels. It was therefore assumed that the individual IL-6 expression could 
correlate with the number of tumor foci in the same animal. To test this 
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hypothesis, a linear regression analysis was performed. The data is shown in 
Figure 4.14 B and demonstrates that the expression level of IL-6 does not 
significantly correlate with number of tumor foci. 
A 
 
 
 
 
              B 
 
 
 
 
 
 
Figure 4.14: Analysis of TNFα and IL-6 gene expression after DEN mediated tumor 
induction: A. Casp8f/f and Casp8∆hepa mice were subjected to single injection with DEN 
(25 mg/ kg) at the age of 2 weeks and sacrificed after 24 and 40 weeks, respectively. Gene 
expression was normalized via GAPDH expression levels. Data were calculated as fold 
induction in comparison to untreated Casp8f/f control-mice. B. Linear regression analysis. For 
each DEN-treated Casp8f/f or Casp8∆hepa liver the relative IL-6 expression level (fold induction) 
was plotted against the number of tumor foci. Regression analysis was performed using PRISM 
software. P values < 0.05 were considered statistical significant. 
To further evaluate inflammation in DEN-treated Casp8f/f and Casp8∆hepa 
mice, liver sections were stained with a fluorescence-labeled CD45 antibody. 
CD45, also known as protein tyrosine phosphatase receptor type C (PTPRC) is 
a leukocyte antigen and thus serves as a marker for overall leukocyte 
infiltration. Stained sections were analyzed by fluorescence microscopy and 
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subjected to quantification by counting positive cells in randomly selected 
magnification fields.    
A Casp8f/f Casp8∆hepa  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B  
 
 
 
 
 
Figure 4.15: CD 45 Staining after DEN mediated tumor induction. A. Casp8f/f and 
Casp8∆hepa mice were injected with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 
40 weeks. Liver cryosections were stained with immunofluorescence-labeled CD45-antibody; 
CD45-positive leukocytes are stained in green; total cells were counter stained with DAPI (blue). 
B. Quantification of CD45-positive cells shown in A. For each mouse, three independent 
magnification fields were analyzed. **: p<0.01; *: p<0.05. 
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In good agreement with elevated basal TNF expression levels, Casp8∆hepa livers 
revealed also increased numbers of CD45-positive cells in untreated samples 
(Figure 3.16, top). Interestingly, these mice also showed significantly increased 
CD45-positive infiltrates in livers with advanced HCC (40 weeks post DEN), 
which was barely evident in the control group. Accordingly, enhanced tumor 
formation in Casp8∆hepa mice is associated with inflammation suggesting that 
Casp8 mediates anti-inflammatory properties in the DEN model. 
4.3.6 DNA array analysis links the loss of Casp8 to over-expression 
of DMBT1 
 
 
 
 
 
 
 
Figure 4.16: Casp8f/f and Casp8∆hepa mice (n = 3 each) were treated with recombinant murine 
TNF for 2 hours or left untreated. Liver samples were subjected to RNA isolation and 
subsequent DNA array analysis in cooperation with Prof. M. Müller (Wageningen) of DMBT1 of 
untreated and TNF treated Casp8f/f and Casp8∆hepa mice.  
The present data hinted at tumor suppressive properties of Casp8 due to 
higher tumor progression and proliferating rate in Casp8∆hepa mice. However, 
the molecular mechanisms, how Casp8 antagonized advanced tumor growth, 
remained obscure and the previous experiments suggested that non-apoptotic 
functions of Casp8 might be responsible for these effects. To detect yet 
unknown Casp8-dependent pathways, DNA array analyses from untreated and 
TNF-treated Casp8f/f and Casp8∆hepa mice were performed independent of the 
present work (C. Liedtke, M. Müller and C. Trautwein, unpublished data). This 
approach revealed that a yet poorly investigated gene designated Deleted in 
Malignant Brain Tumors 1 (DMBT1) was de-regulated by ablation of Casp8 in a 
TNF-dependent manner (Figure 4.16). The data revealed that DMBT1 was 
strongly up-regulated by TNF in Casp8∆hepa mice, but not in WT controls. 
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Therefore it was hypothesized that enhanced HCC progression in 
Casp8∆hepa mice could be related to aberrant DMBT1 expression. Consequently, 
DMBT1 expression in DEN-treated mice with early or advanced HCC was 
investigated in more detail.  
4.3.7 Casp8 prevents DMBT1-depending CD133+ cancer stem cell 
activation 
The role of DMBT1 in the liver is poorly understood so far. Initially, it was 
described in the context with medullablastoma formation (Mollenhauer et al. 
1997). In further studies it was shown to be deleted or down-regulated in lung, 
gut, and breast cancers (Mori et al. 1999, Takeshita et al. 1999, Wu et al. 
1999b, Mollenhauer et al. 2004). Interestingly, DMBT1 was over-expressed in 
regenerating liver cells (Bisgaard et al. 2002). Beside its assumed function in 
innate immunity and mucosal protection, it was postulated that DMBT1 is 
involved in epithelial and stem cell differentiation (Tynan et al. 2005).  
To test the possibility that DMBT1 is involved in enhanced HCC 
progression in Casp8∆hepa mice, DMBT1 mRNA levels were determined in 
Casp8f/f and Casp8∆hepa mice 24 and 40 weeks after DEN-treatment (Figure 
4.17 A). Interestingly, DMBT1 was substantially up-regulated (up to 5755 fold) 
in subpopulations of Casp8∆hepa mice after 24 and 40 weeks following DEN-
treatment. Although the differences were not statistically significant due to high 
variation between the mice, Casp8∆hepa animals could be categorized into 2 
subpopulations with either silencing of DMBT1 (expression 0.1 fold or lower 
compared to un-treated controls) or dramatic over-expression (10 - 5755 fold), 
which perfectly reflects the variable distribution of tumor foci and size in these 
animals 40 weeks after DEN treatment (compare Figure 4.9). 
Over-expression of DMBT1 in Casp8∆hepa mice was confirmed on the 
protein level using in situ immunofluorescence stainings on extracted liver 
sections 24 and 40 weeks after DEN treatment, respectively. As shown in 
Figure 4.17 B, DMBT1 expression in Casp8f/f livers was mostly restricted to the 
large liver vessels. In contrast, livers of DEN-treated Casp8∆hepa mice revealed 
overall larger stained tissue areas which were not only restricted to vascular 
structures. 
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Very recent data indicated an involvement of DMBT1 in differentiation of 
oval cells – a postulated liver stem cell population - into hepatocytes (Deng et 
al. 2012). Based on the findings of the present study demonstrating increased 
DMBT1 expression in Casp8∆hepa livers with strong HCC progression, it was 
hypothesized that Casp8 could antagonize DMBT1-mediated activation of liver 
stem cells and subsequent stem cell mediated tumor progression.  
One accepted marker for liver stem cells, but also for tumor stem cells in 
general, is CD133+ (also known as Prominin 1). CD133+ expression identifies a 
population of oval cells with the gene expression profile and function of 
primitive, bipotent liver stem cells (Ma et al. 2007, Yin et al. 2007, Fujii et al. 
2010, Tsuchiya et al. 2009). Interestingly, CD133+ has been recently identified 
as part of the cancer stem cell population responsible for tumorigenesis in brain, 
prostate, and colon cancer (Singh et al. 2003, Singh et al. 2004, Hemmati  et al. 
2003, Richardson et al. 2004, O’brien et al. 2007,  Ricci-Vitiani et al. 2007). 
Several studies have linked CD133+ expression to liver cancer stem cells, 
demonstrating that CD133+ cells from established HCC cell lines displayed 
significant tumorigenic capacity (Ma et al. 2007, Yin et al. 2007).  
To test if high DMBT1 expression could be associated with stem cell 
activation, gene expressing analysis of CD133+ in Casp8f/f and Casp8∆hepa mice 
24 and 40 weeks after DEN-treatment was performed. The data demonstrated 
an up-regulation of CD133+ in both Casp8f/f and Casp8∆hepa mice 40 weeks 
after DEN-treatment. However, Casp8∆hepa mice revealed again to 
subpopulations of livers/HCC showing either normal CD133+ expression 
comparable to controls or marked up-regulation (5 - 25 fold in comparison to 
Casp8f/f mice, Figure 4.17 C). To track CD133+ in these livers, CD133+ 
immunofluorescence stainings in liver sections were performed demonstrating a 
focal strong expression of CD133+ on the surface of Casp8∆hepa liver cells, 
which was not evident in controls (Figure 4.17 D). The simultaneous over-
expression of DMBT1- and CD133+ expression in Casp8∆hepa mice indicated a 
possible connection between these two molecules. Therefore, a linear 
regression analysis of these signals was performed showing a significant 
correlation of both factors (Figure 4.17 E). Accordingly, the data suggests that 
loss of Casp8 triggers increased expression of DMBT1 in the liver leading to 
CD133+ positive (cancer) stem cell activation.  
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Figure 4.17: Analysis of DMBT1 and CD133+ expression after DEN-mediated tumor 
induction. Casp8f/f and Casp8∆hepa mice were subjected to single injection with DEN (25mg/ kg) 
at the age of 2 weeks and sacrificed after 24 – and 40 weeks respectively. Gene expression 
was determined by quantitative real-time PCR and normalized via GAPDH expression levels. 
Data were calculated as fold induction in comparison to untreated Casp8f/f-control-mice. (A, B). 
Determination of DMBT1 expression. A. DMBT1 gene expression. Please note that the fold 
induction is indicated in a logarithmic scale. B. Liver cryosections were stained with 
immunofluorescence-labeled DMBT1-antibody. DMBT1 is stained in green; total cells were 
counter stained with DAPI (blue). (C, D). Determination of CD133+ expression. C. CD133+ 
gene expression. D. Immunofluorescence staining for CD133+ localized on the surface of liver 
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cells. Green: CD133+; Blue: DAPI. ns: not significant. E. Linear regression analysis between 
DMBT1 and CD133+. 
4.3.8 Loss of Casp8 triggers NF-κB-activation in chemically induced 
hepatocarcinogenesis 
Recent studies demonstrated that the DMBT1 promoter contains 
regulatory elements which can bind the transcription factor NF-κB. Accordingly, 
DMBT1 can be up-regulated in a NF-κB dependent manner, e.g. by stimulation 
with TNF or LPS as shown in epithelial cell lines (Rosenstiel et al. 2007). NF-κB 
is a transcription factor involved in immunity, inflammation, cell survival, 
apoptosis (Sarkar et al. 2008), cancer cell invasion and angiogenesis (Helbig et 
al. 2003, Huang et al. 2001, Samant et al. 2007). It consists of the two subunits 
p50 and p65 which are sequestered to the cytoplasm in the inactive state and 
are translocated to the nucleus after appropriate stimulation, where they trans-
activate the expression of target genes. Of notice, NF-κB activity is increased 
especially in poorly differentiated human cancer (Karin 2006).  
To test the hypothesis that increased DMBT1 expression and overall 
enhanced tumor progression in Casp8∆hepa mice could be related to NF-κB 
activation, nuclear extracts from Casp8f/f and Casp8∆hepa livers were isolated 40 
weeks after DEN treatment and subjected to electrophoretic mobility shift 
assays (EMSA) using a NF-κB specific consensus sequence. Interestingly, 50 
% (5/10) of Casp8f/f samples revealed explicit NF-κB activation while this was 
the case in 80 % (8/10) of Casp8∆hepa livers (Fig 3.18 A). Moreover, the overall 
strength of activation (band intensity) was higher in Casp8∆hepa livers compared 
to the matching Casp8f/f control which suggests that Casp8 may act as a NF-κB 
antagonist in DEN-induced hepatocarcinogenesis.  
In order to detect hepatic cells with activated NF-κB, immunostainings of 
livers with HCC were performed using an antibody specific for the p65 subunit. 
Surprisingly, nuclear p65 was not detected within tumor nodules at all, but was 
restricted to tumor-surrounding hepatocytes especially in Casp8∆hepa livers and 
less evident in Casp8f/f tissue 40 weeks after DEN treatment (Figure 4.18 B).  
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Figure 4.18: Enhanced tumor growth in Casp8∆hepa mice is associated with sustained NF-
κB activation and nuclear translocation of p65 in tumor-surrounding liver tissue. Casp8f/f 
and Casp8∆hepa mice were subjected to single injection with DEN (25mg/ kg) at the age of 2 
weeks and sacrificed after 40 weeks. A. EMSA analysis with NF-κB consensus sequence and 
nuclear extracts derived from Casp8f/f and Casp8∆hepa livers. The results of two independent 
experiments is shown in total representing data from n = 10 animals per group. Free probe: 
labeled consensus oligo was not incubated with nuclear protein; -ctrl: negative control derived 
from untreated Casp8f/f and Casp8∆hepa livers, respectively. +ctrl: positive control derived from 
Casp8∆hepa liver 2 hours after partial hepatectomy showing strong NF-κB activation. P65 
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supershift: To prove specific complex formation with NF-κB, nuclear extracts were incubated 
with NF-κB consensus oligo and an antibody directed against NF-κB subunit p65. Formation of 
a new slow migrating complex (supershift) demonstrates NF-κB binding. B. Liver sections were 
subjected to a p65-antibody. P65-positive cells are stained in brown. Top: Overview, original 
magnification 50X. A region of interest is boxed. Bottom: Enlarged view, original magnifications 
200X. P65-positive cells are highlighted by arrows. C. Gene expression analysis of IκBα in 
livers from Casp8f/f and Casp8∆hepa mice. Expression was normalized to GAPDH and calculated 
as fold induction in comparison to untreated Casp8f/f control mice. 
The inhibitor of NF-κB, IκBα, is one of the first target genes of NF-κB and 
usually ensures that NF-κB is only transiently activated through a negative 
feedback loop (Legarda-Addison et al. 2009). Accordingly, IκBα induction may 
indicate either NF-κB activation or repression depending on the cellular context. 
However, during tumor progression (24 - 40 weeks after DEN treatment) 
significant differences in IκBα gene expression between Casp8f/f and 
Casp8∆hepa livers were not detected at any time point as evidenced by 
quantitative real-time PCR (Figure 4.18 C). This data demonstrates that in 
general IκBα gene expression is not changed in DEN-induced tumor 
progression and thus does not contribute to the different NF-κB activation and 
tumor progression observed in Casp8∆hepa mice. 
4.3.9 Enhanced hepatic tumor formation in Casp8∆hepa mice is 
associated with down-regulation of cell cycle inhibitors p21 
and p27 
Tumorigenesis is usually associated with de-regulated cell cycle involving 
either up-regulation of cell cycle promoters (e.g. the Cyclin D1, Sugimura 1992, 
Tanigami et al. 1992, Zhang et al. 1993, Nishida et al. 1994), or down-regulation 
of cell cycle inhibitors such as p21 and p27 (Malumbres & Barbacid 2001). 
Several reports indicated that Casp8 also bears non-apoptotic functions and 
may affect cell cycle regulation (Maelfait & Beyaert 2008) although the precise 
mechanisms are poorly understood. To test, if ablation of Casp8 directly triggers 
cell cycle activation during hepatocarcinogenesis, the expression of p21 and 
p27 was determined in detail in untreated Casp8∆hepa mice and Casp8f/f controls 
(baseline expression) but also in animals treated with DEN for 24 weeks (tumor 
initiation) or 40 weeks (advanced tumor progression). The cell cycle inhibitor 
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p21 inactivates cyclin E/A/Cdk2 kinase complexes and is directly regulated by 
p53. Similarly, the cyclin-dependent kinase inhibitor p27 inhibits especially 
cyclin E/CDK2-complexes and it has been shown that down-regulation of p27 is 
associated with poor prognosis of patients with tumors in breast, prostate, 
bladder, lung, glia, liver, larynx, ovary, stomach, and other tissues (Nickeleit et 
al. 2007). Surprisingly, HCC development was not associated with aberrant p21 
gene expression in DEN treated Casp8f/f controls or Casp8∆hepa mice at any 
time point investigated as demonstrated by quantitative real-time PCR (Figure 
4.19 A). Analysis of p27 expression in Casp8f/f-mice revealed a reduced 
expression both 24 and 40 weeks after DEN treatment compared to basal 
expression levels (Figure 4.19 B). These findings are consistent with the idea 
that HCC development correlates with increased cell cycle activity. However, in 
Casp8∆hepa- mice gene expression of p27 was already significantly down-
regulated at basal levels, but more importantly also strongly reduced during 
advanced HCC progression (40 weeks post DEN) when compared to Casp8f/f-
controls. These findings indicate that Casp8 might be necessary to maintain 
sufficient p27 gene transcription in liver homeostasis but also during liver cancer 
formation.  
Cell cycle mediators such as cyclins and cyclin-dependent kinase 
inhibitors are not only regulated by control of gene transcription but also on the 
level of protein translation and through post-translational modifications (e.g. 
phosphorylation, ubiquitin-mediated degradation etc.). Therefore, protein 
expression of p21 and p27 was determined in liver samples from Casp8f/f 
controls and Casp8∆hepa mice with advanced tumor progression (40 weeks after 
DEN-treatment) by western blot analysis (Figure 4.19 C). Efficient Casp8 
deletion in Casp8∆hepa mice was confirmed by probing these samples with a 
Casp8-specific antibody. Interestingly, the experiment revealed that in the 
majority of Casp8f/f-samples (6/7) p21 protein was clearly expressed while p21 
was only barely expressed (1/7 samples) in Casp8∆hepa liver. This finding 
demonstrates that Casp8 is not relevant for transcriptional control of p21, but 
important for regulating its protein stability through yet unknown mechanisms. 
Regarding p27 protein expression, similar results were obtained. p27 was 
detectable in all Casp8f/f-samples, but barely visible in Casp8∆hepa liver samples 
40 weeks after DEN treatment. Accordingly, in Casp8∆hepa mice the p27 protein 
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expression levels were in good agreement with the gene expression profiles 
(compare Figure 4.26 B), again hinting at a role of Casp8 for the transcriptional 
regulation of p27.  
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Figure 4.19: Enhanced hepatic tumor formation in Casp8∆hepa mice is associated with 
down-regulation of cell cycle inhibitors p21 and p27. Casp8f/f and Casp8∆hepa mice were 
subjected to single injection with DEN (25 mg/ kg) at the age of 2 weeks and sacrificed after 24 
and 40 weeks, respectively. (A, B). Gene expression of A. p21 and B. p27 from liver tissue at 
time points indicated was determined by quantitative real-time PCR and normalized via GAPDH 
expression levels. Data were calculated as fold induction in comparison to untreated Casp8f/f 
control-mice. *: p<0.05. C. 40 weeks after DEN treatment, liver proteins were isolated from 
Casp8f/f and Casp8∆hepa mice and subjected to western blot analysis for Casp8, p21 and p27. 
Equal protein loading was confirmed by measurement of GAPDH. For each group proteins from 
seven independent mice were loaded.  
In summary these data demonstrate that loss of Casp8 primes liver cells for 
enhanced proliferation through down-regulation of cyclin-dependent kinase 
inhibitors via several independent mechanisms. 
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5 Discussion 
Hepatocellular carcinoma represent one of the most common primary 
cancers with growing incidence (Freimuth et al. 2010) and limited therapeutical 
options as these tumors poorly respond to chemotherapy. This indicates that 
hepatoma cells have acquired apoptosis resistance during malignant 
transformation (Liedtke & Trautwein 2012). In this line of evidence, it has been 
demonstrated that the pro-apoptotic mediator Caspase-8 (Casp8) is frequently 
inactivated in human and murine HCC tissue (Liedtke et al. 2005, Soung et al. 
2005). Therefore, the aim of the present study was to test the hypothesis that 
Casp8 might be important for the elimination of premalignant cells and thus 
could be an important tumor suppressor in the liver. For this approach, 
genetically modified mice with a conditional hepatocyte-specific inactivation of 
Casp8 (Casp8∆hepa mice) were subjected to the liver-specific carcinogen 
Diethylnitrosamine (DEN) and analyzed for the immediate acute and long term 
response with respect to apoptosis, inflammation and hepatic tumor formation. 
The study revealed several interesting results. First, loss of Casp8 did 
not affect the immediate response towards acute DEN-mediated liver injury with 
the exception of a premature begin of proliferation in Casp8∆hepa mice towards 
DEN-treatment. Second, the frequency and size of dysplastic liver lesions was 
also similar in Casp8∆hepa mice and controls as analyzed 24 weeks after HCC 
induction. However, Casp8∆hepa mice showed accelerated advanced HCC 
progression 40 weeks after DEN treatment with increased number and size of 
tumor nodules. This was associated with increased hepatic inflammation, 
increased NF-κB activation, down-regulation of the tumor-suppressor p21 as 
well as p27 and the unexpected induction of two genes encoding the putative 
tumor stem cell marker CD133+ and the poorly characterized factor DMBT1 
(Deleted in Malignant  Brain Tumor 1), respectively.  The data hint at a novel, 
non-apoptotic role of Casp8 for the suppression of liver tumors and will be 
subsequently discussed in detail. 
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5.1 Loss of Casp8 does not affect the immediate response 
towards genotoxic acute liver injury 
Administration of DEN to mice is a widely accepted model of 
hepatocarcinogenesis (Farazi & DePinho 2006). When applied at low dose at 
the age of 2 weeks, these animals typically develop tissue dysplasia and small 
tumor nodules within 24 weeks, which further progress to advanced HCC 40 
weeks after induction. When applied at high dose to adult mice, DEN induces 
acute liver injury associated with predominant perilobular necrosis, but also 
apoptosis and a regenerative response that involves the induction of TNF, IL-6 
and compensatory proliferation until the liver damage is repaired (Naugler & 
Karin 2008). 
Very recent data demonstrated that ablation of Casp8 protects from Fas- 
and TNF-mediated liver injury but sensitizes the liver for enhanced necrosis in a 
model of hepatitis induced by the T-cell mitogen Concanavalin A (Liedtke et al. 
2011). Moreover, Casp8 deficiency results in an accelerated onset of 
hepatocyte proliferation and liver regeneration after partial hepatectomy (PH) 
due to premature NF-κB activation (J. Freimuth and C. Liedtke, unpublished 
results). It was therefore hypothesized that ablation of Casp8 could result in 
improved survival and proliferation of premalignant hepatocytes after acute 
DEN treatment. In partial agreement with this idea, Casp8∆hepa mice showed a 
slight but significant increase in the proliferative response to DEN, which was 
restricted to the first 24 hours after treatment. In agreement with recent data, 
Casp8 seemed to prevent premature proliferation accompanied by a longer 
DNA-repair time before cell division (Freimuth, unpublished data). However, the 
present study did not reveal any significant differences in the acute liver injury 
between Casp8∆hepa mice and control animals as demonstrated by comparable 
serum transaminase activities. Of special interest was the determination of the 
apoptotic response towards DEN as Casp8 is the apical caspase in the extrinsic 
apoptosis signaling cascade induced by Fas, TNF, Trail and related death 
ligands. Notably, Casp8∆hepa mice did not reveal significantly less TUNEL 
positive liver cells after DEN treatment compared to control mice. As TUNEL 
staining is not completely specific for apoptosis but may also stain necrotic cells 
under certain circumstances, the enzymatic caspase-3 activity in the liver was 
Discussion 
62 
 
also determined in the experimental setting and confirmed these results. 
Therefore the present data demonstrates that DEN induces - besides necrosis - 
predominantly intrinsic apoptosis which is independent of Casp8. Accordingly, 
Casp8 is not protective in the acute phase of genotoxic malignant 
transformation. Moreover, the data suggests that the regenerative response of 
the injured liver is controlled differentially after PH (Casp8-dependent) or DEN 
treatment (Casp8-independent) as loss of Casp8 results in improved liver 
regeneration after PH which was barely observed following DEN-induced injury.  
5.2 Early hepatic tumor formation is independent of Casp8  
Based on the initial hypothesis that Casp8 might be important for the 
elimination of premalignant hepatocytes, it was expected that Casp8∆hepa mice 
would display enhanced tumor initiation and increased dysplasia. In contrast to 
these expectations, loss of Casp8 resulted in the same number and size of 
dysplastic liver lesions 24 weeks after DEN treatment. These unexpected 
findings were supported by quantification of proliferating hepatocytes in situ 
demonstrating a similar slight increase of proliferation in both Casp8∆hepa mice 
and controls. Interestingly, TUNEL-positive, apoptotic hepatocytes were barely 
detected in either DEN-treated control tissue or Casp8∆hepa mice 24 weeks after 
DEN treatment. These data suggest that the postulated role of apoptosis for the 
defense against chemically induced hepatocarcinogenesis might have been 
over-estimated in the past. This might be especially the case for extrinsic, 
death-receptor mediated apoptosis as lack of Casp8 had no effect on early 
hepatocarcinogenesis.  
5.3 Casp8 protects from advanced HCC progression via non-
apoptotic functions 
Although Casp8∆hepa mice showed a normal acute response towards 
DEN and the same number of dysplastic foci at early hepatocarcinogenesis, 
these mice showed more and larger liver tumors 40 weeks after treatment. This 
key finding of the present study indicates that Casp8 is rather important for 
inhibition of tumor cell growth than for tumor cell elimination hinting at several 
unexpected non-apoptotic functions of Casp8 in the progression of DEN-
induced HCC. It was shown before that acute DEN-mediated liver injury is 
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associated with a transient pro-inflammatory response involving the activation of 
TNF and IL-6 related signaling pathways suggesting that increased expression 
of these cytokines in the acute phase of DEN injury might be related to 
enhanced hepatocarcinogenesis (Naugler & Karin 2008, Sander et al. 2007). 
Interestingly, loss of Casp8 as analyzed in the present study did not result in 
enhanced immediate response towards acute DEN-mediated liver injury despite 
stronger HCC progression. This was especially unexpected as the basal TNF 
expression in Casp8∆hepa mice was significantly increased in comparison to 
control mice in agreement with recent reports (Liedtke et al. 2011). However, 
Casp8∆hepa mice showed a remarkably increased infiltration of CD45-positive 
cells 40 weeks after DEN treatment although TNF- and IL-6-expression did not 
differ significantly between Casp8∆hepa and control mice at this age. As CD45 is 
a well-established marker for leukocytes (Shaw 2002), these data suggest that 
Casp8 might have anti-inflammatory properties in advanced 
hepatocarcinogenesis. 
A second non-apoptotic function of Casp8 involves its direct impact on 
the negative control of the cell cycle activity in the liver. A recent study 
demonstrated that Casp8 keeps the Receptor-interacting kinase RIP1 in check, 
e.g. by proteolytic cleavage. Accordingly, inhibition of Casp8 results in 
accelerated RIP1 activation and prolonged stability (Liedtke et al. 2011). In an 
experimental model of liver regeneration, following partial hepatectomy loss of 
Casp8 – and thus accelerated induction of RIP1 – was shown to be protective 
and resulted in improved onset of compensatory hepatocyte proliferation (J. 
Freimuth and C. Liedtke, personal communication). It was recently 
demonstrated that RIP1 down-regulates the cell cycle inhibitor p27 (Park et al. 
2008). In this line of evidence, the present study demonstrated that p27 was 
significantly down-regulated in Casp8∆hepa livers 40 weeks after DEN treatment. 
As this was the time point where increased HCC progression in these livers was 
first evident, it is tempting to speculate that loss of Casp8 might trigger 
enhanced cell cycle activity at least in part by inhibiting p27 in a RIP1-
dependent manner. However, to further proof this hypothesis, RIP1 expression 
studies in advanced Casp8-deficient tumors will be necessary which was 
beyond the scope of this study. Moreover, abnormalities in protein regulation of 
a second cell cycle inhibitor were investigated. Beside cell cycle regulation, p21 
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modulated DNA repair processes and was important for stem cell maintenance 
(Abbas & Dutta 2009). Although no significant differences in mRNA expressions 
of p21 were detected, the protein level of p21 was decreased in Casp8∆hepa 
mice. 
As recently reported, another consequence of de-regulated RIP1 
expression in Casp8-deficient mice could be enhanced NF-κB activation or 
programmed necrosis (Liedtke et al. 2011, Festjens et al. 2007, Vandenabeele 
et al. 2006). However, no signs of programmed necrosis were observed in 
DEN-treated Casp8∆hepa mice (data not shown), whereas electrophoretic 
mobility shift analysis revealed increased NF-κB activity in a subset of 
Casp8∆hepa livers with advanced HCC 40 weeks after treatment. Interestingly, a 
subpopulation of Casp8∆hepa mice showed increased expression of the death 
ligand Fas 24 weeks after DEN treatment. Even though the apoptotic pathway 
was blocked by the lack of Casp8, other pathways could be triggered and could 
lead to an enhanced NF-κB activity (Ahn et al. 2001). Thus it is likely that 
elevated NF-κB activity contributes to enhanced tumor growth in Casp8∆hepa 
mice. To definitely prove this hypothesis, Casp8∆hepa mice with an additional 
block of NF-κB signaling, e.g. mice with simultaneous ablation of Casp8 and the 
NF-κB essential modulator (NEMO), could be treated with DEN and analyzed 
for reversion of enhanced HCC progression in future experiments.  
Unexpectedly, the present study also revealed that in a subpopulation of 
DEN-treated Casp8∆hepa livers, the poorly characterized factor Deleted in 
Malignant Brain Tumors (DMBT1) was substantially up-regulated on the gene 
expression level, which correlated with enhanced expression of the postulated 
tumor stem cell marker CD133+. Although the differences in expression levels 
between Casp8∆hepa mice and controls were not statistically significant due to 
high variations, this observation could be relevant since increased tumor growth 
was also only observed in a subpopulation of Casp8-deficient livers. DMBT1 
expression was investigated as preliminary data from microarray analysis hinted 
at a de-regulation of this factor in TNF-stimulated Casp8∆hepa livers (C. Liedtke, 
personal communication, data not shown). The current knowledge about the 
function of DMBT1 in the liver is very limited. Recent studies hinted at a 
connection between DMBT1 and oval cells in hepatitis-B-virus related liver 
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diseases (Deng et al. 2012). It was suggested that an inflammation-related up-
regulation of DMBT1 could stimulate the differentiation of oval cells into 
hepatocytes. Moreover, aberrant DMBT1-expression was associated with brain 
and epithelium tumors (Mollenhauer et al. 1997, Wu et al. 1997, Braidotti et al. 
2004). Interestingly, the gene promoter of DMBT1 contains several NF-κB-
responsive elements (Rosenstiel et al. 2007) suggesting that DMBT1 up-
regulation could be the consequence of increased NF-κB activity. The 
mechanistical link between Casp8 deficiency, DMBT1 expression and 
enhanced HCC progression could not be clarified within the present study. 
However, to explain these findings in line with published data and own 
observations, the following hypothesis (illustrated in Figure 5.1) is proposed: 
Albumin is expressed in hepatocytes and a sub-population of ductular 
cells such as cholangiocytes and oval cells (Bettermann et al. 2010). The latter 
ones are considered potential liver stem cells (Sell 1990, Michalopoulos 2007, 
Tanaka et al. 2011). Accordingly, alfp-cre mediated conditional inactivation of 
Casp8 could potentially result in Casp8-deficiency in hepatocytes, 
cholangiocytes and oval cells. Loss of Casp8 triggers enhanced RIP1 activity 
(Liedtke et al. 2011, J. Freimuth and C. Liedtke, unpublished data). In turn, 
RIP1 down-regulates the tumor-suppressor p27 (Park et al. 2008) and further 
up-regulates NF-κB (Festjens et al. 2007, Biton & Ashkenazi  2011). Down-
regulation of p27 in the liver is not sufficient to induce spontaneous HCC (Blain 
et al. 2003, Møller et al. 2000). However, together with a second oncogenic 
stimulus such as DEN, enhanced tumor progression in the liver seems to be 
plausible. One target of NF-κB is DMBT1. Although poorly characterized yet, 
DMBT1 activation could trigger the activation of a more aggressive CD133+ 
positive stem cell population in the cholangiocyte/oval cell compartment, which 
is suggested by the correlation of DMBT1 and CD133+ expression levels in 
Casp8-deficient HCC. As a final consequence, a sub-population of Casp8∆hepa 
mice is prone to stronger HCC progression after DEN treatment.  
Although several aspects of this hypothesis have to be investigated in 
more detail, the present study clearly suggests that a systemic inhibition of 
Casp8 in hepatitis patients (e.g. using low-molecular inhibitors) might bear the 
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risk of increased hepatocarcinogenesis, which will be discussed in the following 
paragraph.  
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Figure 5.1: Proposed Tumor Model: Suggested model to explain 
enhanced HCC progression in DEN-treated Casp8∆hepa mice. 
Further explanations are given in the text. 
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5.4 Protective- and harmful effects of Casp8 depend on the 
tissue environment  
Several recent studies described different and in part even opposing 
effects of a Casp8 inactivation in different liver injury models. So far, at least 
four different settings have been investigated. In an acute liver injury induced by 
the Fas-activating antibody Jo2 or by a combination of lipopolysaccharide/D-
galactosamine, 90% mortality in control mice, but 100 % survival of Casp8∆hepa 
mice are detected. Therefore, ablation of Casp8 seems to be protective in a 
pure pro-apoptotic tissue environment (Liedtke et al. 2011). 
The T-cell mitogen Concanavalin A (ConA) triggers inflammation similar 
to virus-induced hepatitis involving CD4-positive T-cells, natural killer cells and 
macrophages. Of notice, this liver injury involves predominantly liver cell 
necrosis with some minor apoptosis. Under these circumstances, loss of Casp8 
was shown to be harmful as it triggers further tissue necrosis in the liver in a 
RIP1-related manner recently designated as programmed necrosis or 
necroptosis (Vandenabeele et al. 2010). 
In a model of liver regeneration following partially hepatectomy, ablation 
of Casp8 was shown to be protective due to premature activation of RIP1 and 
NF-κB and subsequently accelerated onset of cell cycle activation (J. Freimuth 
and C. Liedtke, unpublished data).  
Genetic inactivation of the NF-κB essential modulator (NEMO) in 
hepatocytes (NEMO∆hepa) leads to a complete block of NF-κB-signaling and 
results in a complex phenotype involving spontaneous hepatitis, basal liver 
apoptosis and fibrosis. Interestingly, these mice spontaneously develop HCC 
within 9 - 12 month with 100 % incidence (Luedde et al. 2005). In this very 
complex in vivo model, additional ablation of Casp8 revealed bivalent effects 
(Liedtke et al. 2011): Juvenile Casp8∆hepaNEMO∆hepa mice developed serious 
liver necrosis and cholestasis in a RIP1-related manner. However, these mice 
were completely protected from the development of HCC suggesting that Casp8 
may act as an oncogene in a chronic, pro-apoptotic environment. 
In sharp contrast, the present study defined Casp8 as a moderate tumor 
suppressor in the DEN model. In line with these findings, the study revealed 
that DEN-induced hepatocarcinogenesis is barely associated with Casp8-
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mediated apoptosis. The clinical relevance of these findings has to be carefully 
determined in future investigations. Clinical HCC usually arise on base of 
chronic inflammation, which is not the case for the DEN model. However, these 
DEN-induced tumors resemble a small group of HCCs which have a poor 
prognosis (Lee et al. 2006). In conclusion, Casp8 can mediate oncogenic or 
tumor-suppressive effects depending on stimuli and tissue environment.  
5.5 Final conclusions and Outlook 
At present, low molecular caspase inhibitors are considered as a 
potential new therapy option due to their ability to reduce hepatocytes apoptosis 
and thus overall liver injury, hepatic inflammation and hepatic fibrosis (Canbay 
et al. 2004). Several clinical studies indicated that these inhibitors could be used 
in patients and might be beneficial for treatment of several liver diseases 
(Masuoka et al. 2009). However, as discussed before, inhibition of caspases 
could also be a risk factor for hepatocarcinogenesis due to the assumed 
function of caspases to eliminate premalignant cells. The present work defined 
Casp8 as a tumor suppressor at least during chemically induced 
hepatocarcinogenesis. Interestingly, extrinsic apoptosis per se does not seem 
to play a major role for the inhibition of DEN-induced tumorigenesis. Instead, it 
appears that rather non-apoptotic functions of Casp8 seem to play a role in 
suppression of hepatocarcinogenesis. Thus, it should be carefully examined in 
further pre-clinical studies, if the advantage of treatment with caspase inhibitors 
in several liver diseases is accompanied by an increased risk of stem cell 
activation and hepatocarcinogenesis. Additionally, the precise classification of 
the underlying liver disease and microenvironment (apoptotic versus necrotic 
injury) becomes more important due to the several signal-dependent Casp8-
functions (pro-apoptotic, anti-necrotic or anti-proliferative) and has to be 
carefully determined before initiation of an anti-caspase therapy.   
In conclusion therapeutical inhibition of Casp8 in patients – which is 
already technically possible – should be handled with exceptional caution as it 
could even increase the risk for progression from chronic hepatitis to 
accelerated tumor growth.   
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6 Summary 
Caspase-8 (Casp8) is the apical protease essential for the initiation of 
extrinsic apoptosis via activation of a caspase cascade. A role of Casp8 for 
preventing Hepatocellular Carcinoma (HCC) has been postulated. However, 
several studies revealed tumor suppressive, but also tumor promoting 
properties of Casp8 depending on the tissue environment. Therefore, the aim of 
this study was to investigate if Casp8 acts as tumor suppressor in the chemical 
model of diethylnitrosamine (DEN)-induced hepatocarcinogenesis using 
conditional, hepatocyte-specific Casp8 knockout (Casp8∆hepa) mice.  
Using a model of DEN-induced acute liver injury, it was demonstrated that 
loss of Casp8 did not substantially affect the immediate reaction towards 
genotoxic acute liver damage. However, the start of compensatory proliferation 
was slightly accelerated in Casp8∆hepa mice hinting at a shortened phase of 
DNA-repair in these animals. Interestingly, loss of Casp8 was not associated 
with reduced liver apoptosis after acute DEN treatment demonstrating that liver 
damage in the DEN model is Casp8-independent. In further studies, a low-dose 
DEN model was applied to induce HCC in Casp8∆hepa mice and wild type 
controls (Casp8f/f). 24 weeks after HCC induction, the frequency and size of 
dysplastic liver lesions were similar in Casp8f/f and Casp8∆hepa mice 
demonstrating that Casp8 does not prevent tumor initiation in the DEN model. 
However, 40 weeks after DEN treatment HCC progression was substantially 
enhanced in Casp8∆hepa mice as measured by increase tumor number and size. 
Detailed analysis revealed that Casp8∆hepa mice showed increased hepatic 
inflammation and accelerated NF-κB-activation after DEN treatment. Moreover, 
loss of Casp8 in advanced HCC resulted in decreased levels of the cell cycle 
inhibitors p21 and p27. Finally, an induction of the putative tumor stem cell 
marker CD133+ was demonstrated in Casp8∆hepa mice which was significantly 
correlated with an up-regulation of the poorly characterized factor DMBT1 
(Deleted in Malignant Brain Tumor 1). In summary, the present study highlights 
novel, non-apoptotic properties of Casp8 for the suppression of liver tumors 
potentially by regulating cell cycle inhibition, hepatic stem cell- and NF-κB-
activation. Accordingly, therapeutical inhibition of Casp8 in hepatitis patients – 
which is currently tested in clinical trials – should be handled carefully as it 
could increase the risk of hepatocarcinogenesis.  
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7 Zusammenfassung 
Caspase-8 (Casp8) ist die apikale Protease im extrinsischen Apoptose-
Signalweg und bewirkt die Aktivierung einer nachgeschalteten Caspasen-
Kaskade.  Aufgrund dieser Funktion wird eine Beteiligung von Casp8 bei der 
Suppression von Hepatozellulären Karzinomen (HCC) postuliert. Allerdings 
zeigten unabhängige Studien nicht nur tumor-suppressive, sondern auch 
onkogene Eigenschaften von Casp8 auf. Ziel der Arbeit war daher zu 
untersuchen, ob Casp8 in einem Modell der Diethylnitrosamin (DEN)-
induzierten Hepatokarzinogenese Tumorsuppressor-Eigenschaften besitzt. 
Diese Frage sollte mit Hilfe von konditionalen, hepatozyten-spezifischen Casp8-
knockout-Mäusen (Casp8∆hepa) geklärt werden.  
In einem Modell der akuten DEN-induzierten Leberschädigung wurde zu-
nächst gezeigt, dass Casp8 die unmittelbare Reaktion auf diese gentoxische 
Leberschädigung nicht beeinflusst. Allerdings bewirkte die Deletion von Casp8 
eine leicht beschleunigte Leberregeneration und dadurch indirekt eine verkürzte 
DNA-Reparatur. Die Deletion von Casp8 war nicht mit einer verminderten 
Leberapoptose assoziiert. Daher verläuft die DEN-induzierte akute 
Leberschädigung Casp8-unabhängig. Mit Hilfe von DEN wurden in  Casp8∆hepa 
Mäusen und  Casp8f/f Kontrollen HCC induziert. Es wurde gezeigt, dass Casp8 
die Initiierung von Lebertumoren nicht blockiert, da beide Gruppen  24 Wochen 
nach Tumorinduktion eine ähnliche Anzahl und Größe von dysplastischen Le-
berläsionen aufwiesen. Allerdings präsentierten Casp8∆hepa Mäuse 40 Wochen 
nach DEN-Injektion deutlich mehr und signifikant größere Tumorknoten und 
somit eine stärkere Tumorprogression im Vergleich zu Kontrolltieren. Detaillierte 
Analysen wiesen auf eine erhöhte Entzündung, verstärkte NF-κB Aktivität sowie 
eine Herabregulation der Zellzyklus-Inhibitoren p21 und p27 in DEN behan-
delten Casp8∆hepa Mäusen hin.  Zusätzlich  führte der Verlust von Casp8 zu ei-
ner erhöhten Induktion des Stammzellenmarkers CD133+, die signifikant mit 
der Induktion  des  Proteins DMBT1 korrelierte. Zusammenfassend zeigt diese 
Studie neue, nicht-apoptotische Eigenschaften von Casp8 bei der Suppression 
von Lebertumoren auf und deutet darauf hin, dass diese Protease den Zellzyk-
lus sowie die Aktivierung von Leberstammzellen und NF-κB steuern kann. Die 
Daten deuten an, dass der aktuell diskutierte Einsatz von Casp8-Inhibitoren bei 
Hepatitis-Patienten ein erhöhtes HCC Risiko bewirken könnte. 
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